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ABSTRACT 
 
Genetic variation in haptoglobin, a plasma protein, has been reported to be associated 
with susceptibility to and the rate of HIV/AIDS progression. The purpose of this study 
was to investigate the influence of haptoglobin polymorphism on HIV/AIDS in black 
South Africans. Polymorphism in the coding region of the haptoglobin gene was detected 
by direct DNA and allele-specific amplification. Polymorphism in the coding region of 
the gene was detected by amplification of DNA and by polyacrylamide gel 
electrophoresis of plasma protein. A statistically significant association was observed 
between allele -61C and resistance to HIV infection. The Hp0 phenotype, in which no 
haptoglobin protein is detected, was associated with HIV status and some promoter 
genotypes. Since in our study population there were a few samples with usable clinical 
data , further investigations need to be done to confirm the association of the -61C allele 
and the Hp0 phenotype with the risk of HIV infection. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Genetic evolution and infectious diseases  
Numerous parasitical, viral and bacterial infectious agents initiate responses of the 
immune system of the host. Infectious agents are capable of influencing evolution 
of the host species. The evolutionary changes in the host may cause shifting 
selective pressures on the infecting agent (McMichael and Klenerman, 2002; 
Borghans et al, 2004). Adaptation system can be demonstrated by human 
immunodeficiency virus (HIV) and the cells of the human host’s immune system. 
After infection by HIV, the virus replicates at the host makes antibodies against 
the virus. However, because the virus mutates at a very high rate during reverse 
transcription, mutants arise the escape the antibodies, and attack the CD4+ cells. In 
this process, HIV kills CD4+ cells and selects against the host in general; CD4+ 
cells attack specific strains and select against non-mutated strains and HIV strains 
that have a low replication rates (Plumelle, 2003).  
Host and pathogens exert strong selective pressures on each other. These pressures 
lead to the two organisms affecting each other’s evolution, the process called 
coevolution. An example of coevolutionary system is a human host gene CCR5 
and a poxvirus. The CC-chemokine receptor 5 (CCR5) is one of the coreceptor 
proteins for HIV. The CCR5-∆32 deletion confers resistance to HIV infection and 
the rate of the disease progression (section 1.3) (Dean and O’Brien, 1997; O’Brien 
and Moore, 2000). The deletion allele was selected in Europe by incessant 
smallpox epidemics more than 2000 years ago (Hopkins, 2002; Galvani and 
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Slatkins, 2003). The CCR5∆32 allele age is estimated between 275 and 1 875 
years (Stephen et al, 1998). To date, the frequency of this allele is estimated at an 
average of 10% in European populations (Dean et al, 1996). Geographic 
distribution of smallpox correlates with the frequencies of CCR5∆32 in Europe. 
Moreover, both poxvirus and HIV use chemokine receptors to enter cells. Thus, 
CCR5∆32 could confer resistance to both poxvirus and HIV (Galvani and Slatkin, 
2003).  
The ability of the HIV to mutate rapidly and escape immune recognition makes it 
difficult to control HIV infection. The escape mutations occur at critical positions. 
One escape mutation is the amino acid substitution within the HLA-restricted 
cytotoxic T lymphocyte (CTL) epitope that hinders epitope-HLA binding. In that 
way, the mutants escape recognition by HLA (Fig 1.1) (Moore et al, 2002). The 
polymorphisms in HIV are a result of selective pressure from HLA and are HLA 
class I allele-specific (Moore et al, 2002; McMichael and Klenerman, 2002). 
Other HLA types select epitopes that for structural and functional reasons are 
harder to mutate without compromising virus survival (Fig 1.1). HLA B27 and 
HLA B57 select such epitopes. Individuals with these alleles fight the HIV 
infection better than individuals carrying other HLA alleles (Moore et al, 2002; 
McMichael and Klenerman, 2002).  
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Fig 1.1.  HLA molecules on the surface of the CTLs direct the CTL response to 
specific epitopes within the HIV pol protein. Some of these CTL responses exert 
selective pressures on the virus which lead to viral escape mutants that are either 
not recognized by HLA or fail to interact with T cell receptors (left). Other 
responses are directed against epitope regions that are structurally or functionally 
constrained which may select slowly or not select at all (right) (McMichael and 
Klenerman, 2002). 
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Selective pressures modifying genes to confer a better adaptation to environment 
may select for alleles that enhance susceptibility (Bottini et al, 1999) or resistance 
to other diseases (Galvani and Slatkin, 2003). Identification of the genetic changes 
that provide protection against diseases could lead to more effective treatment 
methods.   
 
1.2 HIV/AIDS 
1.2.1 HIV types and its origins 
AIDS, or Acquired Immunodeficiency Syndrome, was first recognised in the early 
1980’s, and has grown to be a devastating global epidemic. AIDS is caused by 
Human Immunodeficiency Virus or HIV (Barré-Sinoussi et al, 1983; Gallo et al, 
1984; Levy et al, 1984). HIV belongs to a family of viruses called lentiviruses, a 
subfamily of the retroviruses, which have genes composed of ribonucleic acid 
(RNA) molecules (Gaynor, 1992). Lentiviruses other than HIV have been found 
in nonhuman primates, chimpanzees. In these primates the virus is called Simian 
Immunodeficeincy Virus or SIV (Gao et al, 1999). 
 
There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for global 
AIDS, while HIV-2 is largely confined to West Africa and has tended to spread to 
other countries with strong links to this region of Africa, such as France (O’Brien 
and Dean, 1997; Matheron et al, 2003).  
HIV-1 is a highly variable virus which mutates very readily. Therefore there are 
many genetically different strains of HIV-1, which are classified according to 
groups and subtypes. There are three groups: M, N and O (Yang et al, 2000). 
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Within the HIV-1 M-group there are ten HIV-1 subtypes: subtypes A to J.  The 
subtypes are unevenly distributed throughout the world. The most common 
subtype in South Africa is subtype C (Swanson et al, 2003).  
It is now generally accepted that HIV is a descendent of SIV (Gao et al, 1999; 
Georges-Courbot et al, 1998). The virus crossed over from chimpanzees to 
humans perhaps as a result of exposure to the blood during killing and eating them 
for food. This process of species crossing is called zoonosis and is not uncommon 
a source for novel pathogenesis in humans (Gao et al, 1999; Weber and Alcorn, 
2000). 
HIV-1 is most similar in sequence and genomic organisation to viruses found in 
chimpanzees (Fig 1.2).  However, some subspecies of chimpanzees harbour an 
SIVcpz strain that is genetically divergent from HIV-1. The chimpanzee 
subspecies that harbours SIVcpz closely related to HIV-1 is Pan troglodytes 
troglodytes. The natural habitat of Pan troglodytes troglodytes coincides with 
areas of group M, N and O epidemicity. Thus, the genetic relatedness and 
geographic coincidence suggest that Pan troglodytes troglodytes is a reservoir for 
HIV-1 (Gao et al, 1999).   
 HIV-2 is phylogenetically closely related to SIV harboured by sooty mangabey 
monkeys, SIVsm (Fig 1.2). The epicenter of the HIV-2 coincides with the natural 
habitat of wild-living sooty mangabey monkeys. Thus, the primate reservoir of 
HIV-2 has been clearly identified as the sooty mangabey monkey (Gao et al, 
1999; Georges-Courbot et al, 1998). 
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Fig 1.2. A phylogenetic tree of HIV/SIV constructed from RT region (pol).  All 
the HIV-1 strains formed a cluster with SIVcpz. HIV2 clustered with SIVsm. The 
numbers at nodes indicated bootstrap values in 1000 replication. Six primate 
lentivirus lineages are indicated by brackets (Takemura and Hayami, 2004). 
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1.2.2 Epidemiology 
AIDS is one of the major causes of death worldwide since the outbreak of the 
disease. Globally, about 40 million people were living with HIV/AIDS in 2003; 5 
million of them were newly infected in 2003 (UNAIDS 2003). In 2003 alone, an 
estimated 3 million deaths were reported to have been caused by AIDS-related 
diseases.  A total of 27.8 million people died of AIDS-related diseases from the 
beginning of the epidemic until the end of 2001, of whom 4.3 million are children 
less than 15 years of age (UNAIDS 2003). Sub-Sahara Africa is the world’s most 
affected region.  About 26.6 million people were living with the virus in this 
region in 2003. HIV prevalence considerably varies across the continent and the 
islands that fall under it; the range is between 1% (in Mauritius) and about 40% 
(in Botswana) (UNAIDS 2001, 2002). 
 
In South Africa, the first cases of HIV were reported in 1982. These cases were 
mainly amongst white gay men (Ras et al, 1983). Since then, the number of HIV 
cases has been increasing. Between 1990 and 2002, the prevalence has increased 
from 0.8% to 26.5% (Fig 1.3) (Shisana and Simbayi, 2002). In 2001, 
approximately 5 million people in South Africa were infected by HIV.  AIDS 
claimed the lives of 360 000 people in South Africa in 2001 (Dorrington et al, 
2001; UNAIDS 2002).  
  
 
 8 
 
Fig 1.3. HIV prevalence rate in South Africa. The epidemic has increased from 
0.8 to 26.5% between 1990 and 2002 (Shisana and Simbayi, 2002; UNAIDS 
2002). 
 
Two surveys were conducted across all nine provinces of South Africa in 2002. 
The first study was based on data taken from the Department of Health. The study 
contacted women attending antenatal clinics in all the provinces. The figures 
showed that 26.6% women who attended antenatal clinics nationally in 2002 (Fig 
1.4) were infected. Kwa-Zulu Natal and Gauteng were leading with 36.5 and 
31.6%, respectively (UNAIDS, 2002).  
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These figures, show prevalence amongst sexually active women only; the 
conclusions cannot be applied to non-sexually active women, the elderly, men and 
children. Sampling in the second study was different from the one above. The 
Nelson Mandela study looked at proportional cross-section of society in all nine 
provinces (Shisana and Simbayi, 2002). The results of this study suggested that 
KwaZulu-Natal did not have the highest HIV prevalence in 2002 as shown by the 
Health department study, but rather the Free State and Gauteng. The Nelson 
Mandela study found that 11.4% of overall population in South Africa was 
infected with HIV in 2002 (Shisana and Simbayi, 2002). Despite the difference in 
figures between the two studies, one thing clear is that South Africa has high HIV 
prevalence, and it is still increasing. There is a huge challenge facing the fields of 
prevention, care and science.     
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Fig 1.4.   HIV/AIDS prevalence in South Africa: Provincial statistics (UNAIDS, 
2002). 
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1.2.3 How does the virus work? 
The healthy body’s immune system fights off infections with a combination of 
cellular and chemical responses. HIV infects the key components of the immune 
system, the white blood cells called CD4+ lymphocytes or T-helper cells. This 
infection progressively depletes the CD4+ cells in the blood; eventually causing 
AIDS when the immune system becomes compromised and it can no longer fight 
off diseases. This leaves the host subject to infection from a wide array of 
infectious agents, many of which do not usually adversely affect healthy people 
(Dean et al, 1996). Often, when someone is said to have died of AIDS, the real 
cause of death is usually TB, pneumonia, or some other disease which took hold 
because of the disabled immune system (Nissapatorn et al, 2003).  
 
Like all viruses, HIV uses the host’s cellular machinery to enter the cell, replicate 
and produce disease (Saah, et al, 1998; Gaynor, 1992; Bednarik and Folks, 1992). 
HIV infection begins when the viral particle enters the cell. This requires CD4+ 
receptors and other ligands, which are part of the host (O’Brien and Dean, 1997). 
After the virus has gained entry into the cell, the viral RNA is converted to DNA 
by HIV reverse transcriptase, an enzyme coded for by retroviruses. Then the 
newly made HIV DNA moves to the cell’s nucleus, where it is spliced into the 
host’s DNA with the help of HIV integrase. The integrated HIV DNA is now 
called provirus (Bednarik and Folks, 1992). The integration of retroviral DNA is 
important for the transcription of new viral copies in the form of messenger RNA 
(mRNA). The mRNA-making process involves host cell’s own enzymes. 
Cytokine proteins that are involved in the normal regulation of the immune 
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system, may also regulate transcription. Molecules such as tumor necrosis factor 
(TNF)-α and interleukin-6 (IL-6), secreted in elevated levels by the cells of HIV-
infected individuals may, help to activate HIV proviruses (Bednarik and Folks, 
1992; Molina et al, 1990). After mRNA has been synthesized in the nucleus, it is 
transported to the cytoplasm for viral protein synthesis (translation). Again, the 
host’s protein-making machinery plays an essential role in the process (Bednarik 
and Folks, 1992).  
 
1.2.4 Factors affecting HIV/AIDS progression 
HIV is slow to cause illness in comparison to other viral infections like influenza, 
and many people may be infected for years without knowing it. Time from 
infection with HIV to AIDS varies from a few months (Isaksson et al, 1988) to 20 
years (Muzon et al, 1995; Matheron et al, 2003). This large survival difference is 
dependent on a number of factors: pathogenecity of the infecting virus (O’Brien 
and Dean, 1997; Matheron et al, 2003), CD4+ lymphocytes in the peripheral 
blood (Carré et al (1998), behaviour (Farzadegan et al, 1996), anti-immune 
response (Ullum et al, 1999),  viral load (Mellors et al, 1995; Mellors et al, 1996; 
Carré et al, 1998), and genetic make-up (Haynes et al., 1996; Ullum et al., 1999). 
These factors are probably involved both alone and in combinations to affect the 
rate at which HIV/AIDS progresses.   
 
The progression of HIV to AIDS is characterised by gradual depletion of CD4+ 
cells. A CD4+ cell count of ≤ 200/µl is predictive of AIDS or the onset of AIDS 
(Carré et al, 1998). Viral load (the number of viral particles in the blood) is highly 
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predictive of the rate of disease progression: individuals with low viral load 
progress more slowly than those with higher level of the virus in their blood.  
High viral load in the plasma (>105 copies /ml) in the first year after 
seroconversion is associated with more rapid progression to AIDS (Mellors et al, 
1995; Mellors et al, 1996), but little is known of its predictive value for AIDS in 
the later stage when the CD4+ threshold is reached (Farzadegan et al, 1996). Viral 
load is inversely proportional to the CD4+ cell count in a given host. This is, in 
turn, related to the ability of the host to contain the infection (Saah et al, 1998). It 
has also been shown that viral load is predictive of the risk of transmission. 
Individuals with fewer than 1 500 copies/ml rarely transmit the virus to a partner 
(Quinn et al, 2000). 
 
Another factor that may affect the rate of HIV/AIDS progression is behaviour. 
Farzaden et al (1996) found that in the population they studied, rapid progressors 
(those who developed AIDS less than 3 years after infection) had more lifetime 
sexual partners than the non-rapid progressors. These observations suggested that 
sexually transmitted infections, or maybe an unknown factor, may affect HIV 
disease progression.    
 
Host genetic polymorphisms also account for differences in susceptibility to HIV 
infection and disease progression. These polymorphisms influence various steps 
of the HIV lifecycle (Williamson et al, 2002) and they may either retard 
(McDermott et al, 1998) or accelerate (Martin et al, 1998) progression to AIDS. 
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1.3 Genes involved in HIV/AIDS infection and disease progression 
Variation in some human genes is associated with different responses to 
infections. Genes that are involved in HIV infection work at different aspects of 
infection. There are those whose products are receptors or co-receptors of HIV 
when it enters the cell. Others produce proteins that act on the virus after it has 
gained entry, and those that play a role in the immune system.  
Polymorphisms in the following genes CCR5 (Liu et al., 1999; McDermott et al., 
2000; Martin et al, 1998), HLA (Kaslow et al, 1996; Moore et al, 2002; 
McMichael and Klenerman, 2002), NRAMP1 (Searle and Blackwell, 1998), Toll-
like receptor 4 (Arbour et al, 2000), mannose-binding protein  (Garred et al., 
1997), Interleukin-4 (Nakayama et al, 2002), and haptoglobin (Delanghe et al., 
1998; Quaye et al., 2000; Pulgiese et al, 2002) have been related to variation in 
susceptibility to a number of infections, including HIV. These genes may be 
acting singly or in combination; their effect may be independent, additive or 
multiplicative. These may not be the only genes that are related to susceptibility to 
HIV/AIDS. It is possible that some more genes or genetic variants remain 
undetected.     
 
As mentioned earlier, CC-chemokine receptor 5 (CCR5) is one of the co-receptor 
proteins for HIV (O’Brien and Dean, 1997). The most studied variation in this 
gene is a deletion of 32bp in the coding region (CCR5∆32). This deletion shifts 
the open reading frame to create a truncated protein. This shortened protein 
version fails to reach the cell surface in homozygous individuals, leading to 
resistance to infection by HIV (O’Brien and Dean, 1997; O’Brien and Moore, 
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2000). Individuals who are heterozygous for this variant have reduced levels of 
CCR5 protein on the cell surface. This results in retarded rate of the disease 
progression (Williamson et al, 2000; Dean and O’Brien, 1997; O’Brien and 
Moore, 2000). This genetic variant is extremely rare in Africans (Williamson et 
al, 2000; Martison et al, 1997). There is another less common variant, 
CCR5m303, which also results in the introduction of premature stop codon 
(Quillent et al, 1998). This variant was not found in the South African population 
(Williamson et al, 2000).  
Mutations at the promoter region of CCR5 have been found to either accelerate or 
retard the rate of the disease progression. CCR5 59029-G/G and CCR5P1/P1 
genotypes respectively retard and accelerate progression to AIDS (Martin et al, 
1998; McDermott et al, 1998).  
CCR2 is another HIV co-receptor. A common variant is CCR2-641, which 
substitutes an isoluecine for a valine in the first transmembrane domain of CCR2 
was found to delay AIDS by 2 to 4 years (Michael, 1997). This is the only known 
chemokine co-receptor variant that was significantly higher in Africans compared 
with Caucasians, and there was no significant association between CCR2-641 
variant and HIV status in Africans (Williamson et al, 2000). Strong linkage 
disequilibrium has been demonstrated between CCR5∆32 and CCR2-64I (Struyf 
et al, 2000) and between CCR2-64I and CCR5 59029A alleles (Hancock, 2002). 
CCR5P1/P1 and CCR5 59029A/A genotypes which have been shown to 
independently accelerate HIV/AIDS in Caucasians, were also found to be in 
complete linkage disequilibrium (An et al, 2000). 
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In an epidemiological study done to address validity of overdominant selection at 
the HLA class I loci entailed an analysis of HIV positive individuals (Carrington  
et al., 1999), it was found that heterozygosity at HLA class I loci confers relative 
resistance  to AIDS progression because individuals who are homozygous at 
HLA-A, HLA-B and HLA-C, for example, present a limited repertoire of 
antigenic epitopes compared to individuals who are heterozygous at these loci. It 
has also been shown that individuals carrying HLA B27 and HLA B57 alleles 
have better prognosis after HIV infection than individuals carrying other HLA 
alleles (Moore et al, 2002; McMichael and Klenerman, 2002). 
 
 Mannose-binding protein (mannose-binding lectin) is a member of the collectin 
family of proteins and acts in the first line of defence against various bacterial, 
viral and parasitic infections, before the establishment of the adaptive immune 
protection by B and T cells (Turner, 1996). Polymorphisms in the promoter region 
of the mannose-binding protein gene (Madsen et al., 1995) and the first exon of 
this gene (Lipscombe et al., 1992) have been shown to affect serum concentration 
of mannose-binding protein. Low serum levels of this protein are associated with 
opsonozation defects and impaired phagocytosis (Super et al., 1989). A study 
done by Ezekowits et al (1989) demonstrated that mannose-binding protein was 
able to inhibit HIV. 
This present study was focusing on the genetic polymorphisms in the haptoglobin 
gene which has been shown to be associated with the rate of the disease 
progression. 
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 1.4 Haptoglobin 
Haptoglobin is a type II acute phase plasma α2-sialoglycoprotein (Langlios and 
Delanghe, 1996; Aucan et al, 2002). Haptoglobin is synthesized by hepatocytes 
(Smithies and Walker, 1995; Bowman, 1993) and there is evidence which 
suggests that haptoglobin originates from the organs of reproductive system 
including human uterus (O’Bryan et al, 1997; Olson et al, 1997; Sharpe-Timms et 
al, 2002). Transcription of the haptoglobin gene is induced by interleukin-6 (IL-6) 
in human hepatoma cells. This involves several nucleoprotein-DNA complexes 
associated with specific regions in the promoter region: -157, -111 and -61. These 
protein complexes are 1, 2, 3, 4, 5, 6 and V (Oliviero and Cortese, 1989). In the 
absence of IL-6, proteins responsible for the formation of protein complexes 1, 2, 
3, 5 and/or 6 are bound around and including nucleotide positions -157 and -61, 
flanking the complex V at position -111 (Fig 1.5a). This conformation causes poor 
transcription of the haptoglobin gene. In the presence of IL-6, the IL-6-dependent 
proteins responsible for the formation of complex 4 substitutes the other proteins 
on site -157 and -61 (Fig 1.5b). This conformation results in the activation of 
transcription (Oliviero and Cortese, 1989; Teye et al, 2003).  
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                                                  No IL-6 
 
                                  Complex 1, 2, 3, 5 and 6 proteins 
 A 
 
 
 
 
                     -157                         -111                           -61 
 
                                                                                  Low level of transcription 
 
 
 
                                                  IL-6 present 
B                                     
                                                Complex 4 proteins 
 
 
 
 
                       -157                       -111                   -61 
                                                                                             
                                                                                            Active gene transcription  
 
Fig 1.5. (A) In the absence of IL-6, haptoglobin gene is transcribed at a low level. 
(B) The presence of IL-6 triggers the substitution of the protein complexes at 
positions -157 and -61 by complex 4. This results in active transcription (Oliviero 
and Cortese, 1989). 
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V protein  
   Complex 
V protein  
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1.4.1 Haptoglobin structure and types 
The haptoglobin protein has a tetrameric structure consisting of 2 α and 2 β chains 
encoded by a single gene on chromosome 16q22.3. These chains are generated by 
posttranslational cleavage from a single polypeptide (Yang et al, 1983; Ranyuei et 
al, 1983). The β chains are identical in all individuals, while the α chains are 
polymorphic (Smithies et al, 1962; Langlois and Delanghe, 1996) and found only 
in humans (Black and Dixon, 1968; Teye et al, 2004; Langlois and Delanghe, 
1996).  Although haptoglobin is found in serum of all mammals, this 
polymorphism is only found in humans (Bowman, 1993).  The protein 
polymorphism is due to two codominant alleles Hp1 and Hp2 which result to three 
common genotypes Hp1-1, Hp2-1 and Hp2-2. These genotypes give rise to 
structurally and functionally distinct phenotypes: Hp1-1, Hp2-1 and Hp2-2. Hp1-1 
has α1 chains, Hp2-2 has α2 chains whereas Hp2-1 contains both chains (Fig 1.6A 
and 1.6B) (Koda et al, 2000; Schultze, 1996, Teye et al, 2002; Melamed-Frank, 
2001). Hp1 is further divided into Hp1S and Hp1F. These alleles encode 
polypeptides of equal length, Hp1S and Hp1F respectively (Giblett, 1969; Maeda 
and Smithies, 1985; Asakawa et al, 1999). The two polypeptides differ in the 
number of charged amino acids that make them migrate slowly (Hp1S) or fast 
(Hp1F) during electrophoresis with an acidic buffer. Lysine in Hp1F is substituted 
by glutamic acid in Hp1S at position 54 (Giblett, 1969; Asakawa et al, 1999).  
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Fig 1.6A: Schematic representations of haptoglobin monomers and polymers. 
Hp1 monomer is a monovalent, meaning it can form a bond with one other 
monomer to form a dimer. Hp2 monomer is bivalent and can associate with 2 
different monomers, which could result in circular structure in homozygous Hp2 
individuals.   
                        
                              Hp1-1                                                                            Hp2-1                 
 
 
 
           
 
 
                                                              Hp2-2                        
 
 
 
 
 
 
 
 
 
 
 Fig 1.6B. Structural differences between haptoglobin types. The haptoglobin 
chains are held together by disulfide bonds (Melamed-Frank, 2001). 
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The α2 chain contains two free cysteine residues compared to one in the α1 chain, 
leading to polymerization in Hp2-1 and Hp2-2, while Hp1-1 is a small monomer 
(Fig 1.6A) (Wuyts et al, 2002). 
 The main difference between Hp1 and Hp2 alleles is the duplication of a 1 700 bp 
segment in Hp2 but not in Hp1 (Maeda and Smithies, 1986; Maeda et al, 1984). 
Each of the copies includes two of the exons encoding the α-chain of the 
haptoglobin (Koch et al, 2002).  This duplication was formed by non-homologous 
cross-over between the Hp1S and Hp1F alleles (Fig 1.7) in a heterozygote during 
meiosis (Wuyts et al, 2002; Asakawa et al, 1999; Maeda et al, 1984; Maeda and 
Smithies, 1986).  The crossing over occurred between the fourth intron of Hp1F 
allele and the second intron of the Hp1S allele, between regions 480 of Hp1S and 
region 1271 of Hp1F (Asakawa et al, 1999).  
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Hp1F                                                  
                    480                     1271 
 
 
                                                                                                               
  Hp1S                                                                        480             1271 
                                                                                                                                                                            
 
 
Hp2                                                                                                   
                        480                    1271                 2204            2995 
 
 
 
Fig 1.7: A diagrammatic representation of formation of Hp2 allele by 
nonhomologous cross-over between Hp1F and Hp1S. The numbered blocks and 
circle represent exons. The numbers show position in the gene (Asakawa et al, 
1999).  
   
 
The haptoglobin phenotypes are distinguished by their band pattern on starch 
(Smithies, 1955) or polyacrylamide (Linke, 1984) gel electrophoresis. The 
homozygote Hp1-1 shows a single fast-migrating band of 86 kDa.  The 
homozygote Hp2-2 has a series of slower-migrating bands, whose size is between 
170 to 900 kDa. The heterozygote Hp2-1 displays another series of slow-moving 
bands and weak Hp1-1 band, the sizes of the bands range between 86 and 300 kDa 
(Wuyts et al, 2002; Michel et al., 1996; Smithies, 1955). The slow-moving bands 
2 4 3 5 
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are found only in humans. In other animals including higher primates, haptoglobin 
shows only a single band corresponding to the human Hp1-1 (Langlois and 
Delanghe, 1996). 
 
Another haptoglobin variant, Hp2-1 modified or Hp2-1 mod, is common is black 
Americans, but it is also found in other races (Maeda et al, 1991). The variant 
contains either Hp1F or Hp1S chain and an α chain that is not distinguishable 
from Hp α2 chain, except by its fainter staining (Giblett, 1969). Hp2-1 mod is 
formed when the amount of Hp2 polypeptide synthesized in the Hp2/Hp1 
heterozygote is less than that of Hp1 polypeptide. This unequal expression of the 
polypeptides is the result of polymorphism in the promoter region of haptoglobin 
gene. The polymorphism is a single base pair substitution (A/C) at position -61 in 
one of the interluekin-6 responsive elements of the haptoglobin gene (Maeda, 
1991). The polymorphism has also been reported in Africans (Teye et al, 2003).  
 
The fourth phenotype, Hp0, represents hypohaptoglobinemia or 
anhaptoglobinemia (Giblett, 1969). The Hp0 and Hp1 phenotypes in subSaharan 
African countries have been reported to be linked to a selection pressure by 
malaria parasite (Trape and Fribourg-Blanc, 1988). In Hp0 phenotype, the 
expression of haptoglobin is either absent (anhaptoglobinemia) or very low (less 
than 15 to 20 mg/100ml) to be detected by gel electrophoresis 
(hypohaptoglobinemia) (Giblett, 1969; Delanghe et al, 1998).  Although Hp0 
could be caused by pathological states such as liver dysfunction and haemolytic 
disorders, there is evidence that this phenotype has a genetic origin (Koda et al, 
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1998; Teye et al. 2003, Teye et al, 2004). In Asian populations Hp0 occurs by an 
allelic deletion. The deletion which is 28 kb (Fig 1.8) extends from the promoter 
region of the haptoglobin gene to the exon 5 of the Hpr. The corresponding allele 
is Hpdel (Koda et al, 1998).    
                                          
 
                            
 
Fig 1.8: A schematic representation of the Hpdel breakpoints. The deletion extends 
from the promoter region to exon 5 of Hpr gene. The blocks represent exons and 
their numbers (Koda et al, 1998). 
 
 
The homozygous gene deletion (Hpdel/Hpdel) is associated with haptoglobin 
deficiency or anhaptoglobinemia, whereas the heterozygous genotype, Hp2/Hpdel - 
but not Hp1/Hpdel, is associated with low haptoglobin concentrations or 
hypohaptoglobinemia (Koda et al, 1998).  
1   2      3    4  5   6           7              1    2       3       4    5 
Hp1 or Hp2      Hpr 
Gene deletion (28kb) 
5΄ 3΄ 
  Promoter region 
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Hp0 occurs at frequencies of 10 to 40% in SubSahara Africa (Constants et al, 
1981). Unlike in Asian populations, the cause of Hp0 is not Hpdel, since this allele 
is not found in Africans (Koda et al, 2000; Teye et al, 2003). In Ghanaians the 
Hp2 allele was found to be associated with anhaptoglobinemia. The absence of 
haptoglobin expression in Hp2 allele was reported to be caused by a T to C point 
mutation in the exon 7 at position 6802, leading to the alteration of the codon 247 
from ATT to ACT. The result of this mutation was an I247T substitution of a 
nonpolar amino acid isoleucine to a polar amino acid threonine (Teye et al, 2004).  
None of the anhaptoglobinemic individuals had an Hp1/Hp1 genotype. Hp1/Hp1 
was present in the hypohaptoglobinemic individuals, predominantly as Hp1S (Teye 
et al, 2003). Teye et al (2003) also reported that promoter sequences are 
associated with Hp0: -61C and -101G single nucleotide polymorphisms were 
associated with anhaptoglobinemia and hypohaptoglobinemia, respectively. The 
promoter sequence -101G was found in Ghanaians (Teye et al, 2003), but not in 
Americans (Maeda, 1991).   
 
At the 3΄-end of the haptoglobin gene cluster lies a haptoglobin-related gene, Hpr 
(Fig 1.8).  It is a result of Hp1 gene duplication on chromosome 16, and is found 
only in apes and humans (Giblett, 1969; Maeda, 1984).  The coding sequence of 
Hpr gene appears to be normal and to have no frameshift or splicing mutations 
(Maeda, 1985). Its predicted amino acid sequence differs by 8% from that of the 
Hp1F. The differences appear to be located on the surface of the protein molecule, 
and the regions and specific residues considered to be important for haemoglobin 
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binding are identical in Hp and Hpr proteins. Hpr gene in humans is 2.2kb 
downstream of Hp gene, and it is not expressed in humans (Bensi et al, 1985). 
 
1.4.2 Variation in the haptoglobin promoter region   
Some variation in the noncoding region of the haptoglobin gene has been found in 
African-Americans (Maeda, 1991) and Ghanaians (Teye et al, 2003). As genetic 
variation is higher in Africans than in other populations, Teye et al (2003) found 
three polymorphisms in the promoter region (-242C/T, -191T/G and -101C/G) in 
addition to those previously reported (-55A/G, -61A/C and -104T/A) (Maeda, 
1991). Some of these polymorphisms are linked with certain phenotypes. The -
61A/C base substitution is associated with Hp2-1 mod phenotype (Maeda, 1991). 
As mentioned earlier that position -61 is one of the IL-6 responsive elements, the 
A/C base substitution explains the unequal synthesis of Hp1 and Hp2 polypeptides 
in Hp2-1 mod protein. None of the promoter sequences were linked to Hp0 in 
African-Americans (Maeda, 1991). By contrast, the -61C and -101G promoter 
sequences showed strong association with ahaptoglobinemia and 
hypohaptoglobinemia, respectively (Teye et al, 2003). 
 
1.4.3 Functions of the haptoglobin 
Haptoglobin has several functional properties of biological and pathological 
importance. Haptoglobin types differ in their functional properties (Langlios and 
Delanghe, 1996).  
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1.4.3.1 Haemoglobin binding 
The best known function of haptoglobin is haemoglobin binding. After 
erythrocyte destruction, free haemoglobin is not filtered through the glomeruli 
because of the bound haptoglobin. This reduces the risk of renal damage and the 
loss of haemoglobin and iron. The Hb-Hp complex is transported to the liver, 
where it is broken down in the parenchymal cells by lysosomes. The binding 
property of haptoglobin also prevents accumulation of free radicals generated by 
iron Fe2+ in the presence of H202 (van Vlierberge et al, 2004). The binding of 
haemoglobin to haptoglobin is dependent of the serum haptoglobin concentration 
and haptoglobin type. Hp2-2 phenotype clears haemoglobin circulating in the 
plasma with less efficiency than Hp1-1 and Hp2-1 (Langlois and Delanghe, 1996).  
 
 1.4.3.2 Bacteriostatic effect 
Due to free haemoglobin capture by haptoglobin, heme iron is unavailable for 
bacterial growth. This indicates the role of haptoglobin as part of non-specific 
defence against bacterial invasion (Langlois and Delanghe, 1996). Haptoglobin 
also plays a role in repairing tissue injuries. Exposure of the lung to chemicals, 
organic and inorganic dust makes it vulnerable. Haptoglobin synthesized in the 
lung provides a source of anti-oxidant in the mucous blanket that protects the lung 
(Dobryszycka, 1997) 
 
 1.4.3.3 Agglutination effect of the haptoglobin 
Hp2-2 and Hp2-1 proteins have an ability to agglutinate antigen T4 carried by S. 
pyogenes group A. Hp2-2 serum has higher agglutination titer than Hp2-1. 
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However, haptoglobin is not a true antibody, and it does not activate complement. 
The agglutination effect of Hp2-1 and Hp2-2 is probably mediated via binding 
with lectin-like structure. In contrast, Hp1-1 has no agglutination effect (Langlois 
and Delanghe, 1996).  
 
1.4.3.4 Inhibition of prostaglandin synthesis 
Haptoglobin functions as prostaglandin synthetase inhibitor. The inhibitory effect 
of haptoglobin on prostaglandins synthesis is important in anti-inflammatory 
action. The inhibitory effect of Hp2-2 and Hp2-1 on prostaglandin synthesis is 
less strong than that of Hp1-1 phenotype (Dobryszycka, 1997; Langlois and 
Delanghe, 1996).  
 
1.4.3.5 Angiogenesis 
Haptoglobin has been reported to stimulate angiogenesis, the processes leading to 
the generation of new blood vessels through sprouting from already existing blood 
vessels. The angiogenic effect of Hp2-2 is more pronounced than that of Hp2-1 
and Hp1-1 types (Langois and Delanghe, 1996). 
 
1.5 Involvement of haptoglobin types with HIV/AIDS and other diseases  
Haptoglobin types differ in their biological activities, and they may influence the 
course of a disease (Langlois and Delanghe, 1996). Haptoglobin polymorphism 
has been reported to be associated with infection by TB (Fedoseeva et al, 1993) 
and outcomes after treatment initiation (Kasvove et al, 2000). Hp2-2 phenotype 
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was found to be associated with recurrent pulmonary TB in comparison with Hp1-
1 and Hp2-1 (Eisaev, 1995).  
Fedoseeva et al (1993) reported that Hp2-2 individuals with TB carrying an HLA-
DR2 exhibited large cavities due to tissue destruction, advanced dissemination 
and fast disease progression. In contrast, a study done in Zimbabwe showed no 
association between haptoglobin phenotypes and susceptibility to clinical 
pulmonary TB, however, haptoglobin genotypes had an effect on the outcome of 
TB after initiation of treatment. A high number of Hp2-2 carriers died compared 
to the other haptoglobin phenotypes (Kasvove et al, 2000).  
 
A high incidence of Hp0 was observed among malaria patients in Indian (Joshi et 
al, 1987) and Republic of the Congo (Trape and Fribourg-Blanc, 1988) 
populations, suggesting that anhaptoglobinemia is associated with malaria. Unlike 
in an Indian population, in a Sudanese population Hp1-1 phenotype was found to 
be associated with susceptibility to malaria and development of severe 
complications. The other phenotypes were found to confer resistance (Elagib et al, 
1998). The two above studies show that haptoglobin polymorphism was in some 
way associated with susceptibility to malaria. By contrast, no significant 
association between haptoglobin polymorphism and susceptibility to malaria was 
found in Gambia (Aucan et al, 2002). 
 
Haptoglobin variation has been shown to be associated with diabetes, 
atherosclerosis and cardiovascular diseases (van Vlierberghe et al, 2004). 
Coronary artery lesions and target organ damage in hypertension are commoner 
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among Hp2-2 carriers. For hypertension treatment, Hp2-2 individuals need a more 
complex combination of antihypertension drugs than Hp1-1 individuals (van 
Vlierberghe et al, 2004). Diabetic patients who are homozygous for Hp1 allele are 
protected against the development of vascular complications. It has been proposed 
that the specific interaction between diabetes, cardiovascular disease and 
haptoglobin phenotypes is the result of the impaired clearing capacity of 
glycosylated haemoglobin-haptoglobin complexes from the subendothelial space. 
A delay in the clearing of these complexes result in oxidation of low-density 
lipoproteins to atherogenic oxidized low-density lipoproteins (Asleh et al, 2003)         
 
Haptoglobin polymorphism has been reported to be associated with prognosis in 
HIV infection (Delanghe et al, 1996; Quaye et al, 2000). This effect of 
haptoglobin polymorphism on HIV progression to AIDS and death is related to 
iron stores in the body. As mentioned earlier, haptoglobin functions to capture and 
clear free haemoglobin from the plasma. Hp2-2 binds haemoglobin with less 
affinity, resulting in the retention of iron in Hp2-2 individuals (Delanghe et al, 
1996). All organisms, large and small, require iron to a certain concentration 
(Weinberg, 1978). In humans excess iron has harmful consequences. During iron 
overload, excess iron is stored in parenchymal cells and macrophages (Bothwell et 
al, 1960). This causes direct cytotoxicity, enhancement of infection and increased 
oxidative stress (Weinberg, 1990). Excess iron also accelerates oxidative 
catabolism of ascorbic acid (vitamin C), leading to deficiency of this vitamin 
(Kasvove et al, 2002). Vitamin C provides antioxidant protection because is a free 
radical scavenger. In the presence of excess iron, vitamin C has a pro-oxidant 
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activity. Iron gets trapped within ferritin as Fe3+ and enters the pores of the ferritin 
where it is converted to Fe2+; vitamin C becomes oxidized in the process. Fe2+ 
then leaks out of the ferritin protein and generate free radicals (Delanghe et al, 
2002). In HIV infection, if free haemoglobin is not removed from the plasma, free 
radicals generated activate HIV replication through the activation of the nuclear 
transcription factor NF-κB, an element in the modulatory region of HIV LTR   
and thus results in increased HIV-RNA in the body (Boelaert et al, 1996). The 
mechanism by which free radicals activate NF-κB (Fig 1.9), is through either 
degradation or modification of IκB (a cytoplasmic protein that inhibits NF-κB), 
that results in its dissociation from the p50-p65 complex of proteins that bind and 
activate NF- κB. After the dissociation of the inhibitor from the p50-p65 complex, 
the complex is translocated to the nucleus and binds to the NF-κB. This activates 
the NF-κB factor and subsequently HIV gene expression (Gaynor, 1992).  
 
Harakeh et al (1990) found that vitamin C suppresses HIV reverse transcriptase 
activity and viral replication in HIV-infected cells. Therefore, the combination of 
oxidative stress and vitamin C deficiency may contribute to a high viral load and 
poor prognosis in Hp2-2 individuals. Lower vitamin C concentrations have been 
also observed in healthy individuals with Hp2-2 phenotype compared with the 
other haptoglobin phenotypes (Delanghe et al, 1998). This shows that Hp2-2 
carriers are less protected against haemoglobin/iron-driven oxidation. 
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Fig 1.9: Schematic representation of NF-κB activation. Dissociation of IκB from 
the p50-p65 complex results in NF-κB activation and subsequent activation of 
HIV gene replication (Gaynor, 1992).  
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1.6 Haptoglobin frequencies in South Africans 
The South African black population has nine different subpopulations which are 
distributed across all the nine provinces. These groups are Zulu, Swazi, Xhosa, 
Ndebele (collectively known as Nguni), Tswana, Southern Sotho, Nothern Sotho 
(known as Sotho-speakers), Venda and Tsonga. Although certain groups dominate 
in certain provinces, Johannesburg (in Gauteng province) is a home for all nine 
subpopulations. The South African black ethnic groups originate from Bantu 
expansion and share a common ancestor (Lane et al, 2001); however, there is little 
genetic differentiation among them. The analysis of autosomal DNA and Y 
chromosome polymorphisms revealed that subpopulations that fall under Nguni 
are genetically closely related. The Sotho-speakers formed another cluster, and 
Venda showed close similarity with Tsonga (Lane et al, 2001).    
 
The gene frequencies of haptoglobin show marked geographic differences, with 
lowest Hp1 allele frequency in Southeast Asia and the greatest frequency in Africa 
and South America (Schultze and Heremans, 1966). However, these Hp1 gene 
frequencies are significantly different from higher frequency found among West 
African blacks, and there is evidence suggesting that as one passes south from the 
Congo through Zambia to South Africa, a decrease in the frequency of this gene 
might be demonstrable (Jenkins and Steinberg, 1966). A very large number of 
papers have been written about the haptoglobin allele frequencies in various 
populations throughout the world. Jenkins and Steinberg (1966) and Barnicot et al 
(1959), found that Hp1 gene frequency is 0.47 in Cape Coloureds (Barnicot et al., 
1959); 0.29 and 0.31 in South African Bushmen according to Barnicot et al (1959) 
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and Jenkins and Steinberg (1966), respectively. In a recent study by Koda et al., 
(2000), no Hpdel was observed in a group of Xhosa and European-Africans based 
in Cape Town. Haptoglobin allele frequencies in South African black populations 
are shown in table 1.1.  
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Table 1.1. Distribution of haptoglobin alleles in black South African populations.  
Population Hp1 frequency Hp2 frequency Reference 
Zulu 0.505-0.575 0.425-0.495 Jenkins, (1972); McDermid and 
Vos, (1971a); Hitzeroth and 
Hummel, (1978); Nurse et al, 
(1974) 
Swazi 0.475-0.545 0.525-0.455 Jenkins (1972);  Hitzeroth and 
Hummel (1978) 
Ndebele 0.440-0.480 0.520-0.560 Jenkins (1972); Hitzeroth and 
Hummel (1978) 
Xhosa 0.491-0.535 0.509-0.465  Jenkins (1972); Weissman et al, 
(1982); Giblett et al (1966) 
Venda 
Urban 
0.555-0.586 0.415-0.445 Jenkins (1972); Hitzeroth and 
Hummel (1978); Jenkins (1972); 
Nurse et al (1985) 
Venda  
 Rural 
0.541-0.553 0.456-0.447 Jenkins (1972) and Nurse et al 
(1985) 
N. Sotho  
Urban 
0.585-0.541 0.415-0.459 Jenkins, (1972) and Nurse et al, 
(1974). 
N. Sotho   
Rural 
0.493-0.500 0.507 and 0.500  Jenkins (1972) and Hitzeroth and 
Hummel (1978) 
Tswana 0.493 0.507  Hitzeroth and Hummel (1978) 
S. Sotho 0.511-0.545 0.455-0.489 Giblett et al (1966); Moullec et al 
(1966) 
Tsonga 0.546-0.555 0.445-0.454 Hitzeroth and Hummel (1978); 
Jenkins (1972); Matznetter and 
Spielmann (1969) 
 
 
Although the statistics given above shows that Hp1 is low in Swazi and Ndebele 
groups compared with the other South African populations, the difference in the 
frequencies among South African blacks is small, 0.1 and less. Although their 
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languages differ, they originate from the Bantu expansion, which explains the 
genetic similarity. The difference in frequencies between black South Africans 
and Bushmen is huge. Bushmen show genetic similarity with Khoi. This similarity 
could be due to that they share a common ancestor or due to genetic flow (Nurse 
et al, 1985).   
 
1.7 Problem identification 
Genetic diversity is higher within African populations, than in any other human 
populations in the world. The diversity is observed even between closely related 
or located groups (Jorde et al, 1997, Tishkoff, 2002). It has been mentioned earlier 
that variation in the coding region of the haptoglobin gene was found to be 
associated with the rate of HIV/AIDS progression in Europeans. Similar studies 
have not been done in black South African population. South Africa has the 
highest number of people living with HIV/AIDS. In 2001 alone, 360 000 people 
died of this disease. In this study we looked at the impact of variation in the 
coding region of the haptoglobin gene on the rate of the disease progression in the 
black South Africans population. Because of high genetic diversity in Africans, 
we further detected variation in the upstream noncoding (promoter) region of this 
gene and determined whether the previously reported and additional 
polymorphisms found in black South Africans in this region have any impact on 
the rate of HIV/AIDS progression.  
 
 
 
 36 
CHAPTER 2 
MATERIALS AND METHODS 
2.1 Subjects 
The study population comprises of 163 black South Africans with proven HIV 
infection and 52 samples from a general population taken regardless of HIV 
status. One hundred HIV positive and two HIV negative blood samples along with 
clinical data were collected from willing participants from Johannesburg General 
Hospital. Clinical data collected was self reported and included an estimate of 
number of years after HIV infection, most recent CD4+ cell count, whether the 
participant had ever had TB or not or any other HIV-related diseases. About 80% 
of our participants were woman who had tested positive when they were pregnant. 
They were asked their HIV status on their previous pregnancies or HIV tests to get 
a close estimate of the number of years after infection. Sixty three DNA samples 
from HIV positive people with viral load and CD4+ count data were provided by 
Dr Clive Gray from NICD. Forty blood samples were collected regardless of HIV 
status from willing black students and staff members of the University of the 
Witwatersrand. Ten DNA samples with unknown HIV status were provided by 
Prof Himla Soodyall from the NHLS. Written informed consent to participate in 
this study was obtained from all participants. The study protocol was approved by 
the University of the Witwatersrand Committee for Research on Human Subjects, 
protocol M040221 (Appendix). Blood was aseptically collected into 
ethylenediaminetetraacetic acid (EDTA) tubes.  
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 2.2 DNA isolation 
The blood tubes were centrifuged at 80 rpm for 10 minutes to separate plasma, 
buffy coats (leukocytes) and whole blood. Plasma was stored at -70oC, and later 
used for determination of protein polymorphism. DNA was extracted from the 
leukocytes of the blood samples using QIAmp® Blood DNA kit according to 
manufacturer’s instructions (Qiagen). DNA extraction was carried out in QIAamp 
spin columns which have DNA-adsorbing silica-gel membrane. RNase was used 
to eradicate any traces of RNA or virus that might be in the DNA. The DNA 
adsorbed onto the membrane was eluted in Tris-EDTA (TE) buffer consisting of 
10 mM Tris and 1.0 mM EDTA and stored at -20oC. After purification, the 
concentration and size of the DNA was checked by electrophoresis on 0.8% 
agarose gel in TBE buffer at 70V for 45 minutes. The TBE buffer contained 0.9 M 
Tris, 0.89 M boric acid and 25 mM EDTA. This DNA was used for 
characterization of variation in the haptoglobin promoter and coding regions.  
 
2.3 Detection of variation in the promoter region of haptoglobin gene by 
direct sequencing 
Variation in the promoter region of the haptoglobin gene was detected in 52 
samples collected from 42 HIV positive and 10 individuals with unknown HIV 
status. The detection was done by PCR amplification and direct sequencing of a 
645 bp fragment of the promoter region. This sample size was large enough to 
detect genetic variation that occurs frequently in the population. 
Polymerase chain reaction was carried out in a 50µl reaction volume as described 
by Maeda (1991), except that amplification programmes were slightly modified. 
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The reaction mixture contained 1.25 units of Taq polymerase, 200µM of dNTPs, 
1.5mM MgCl2, 0.2µM of each of the primers and 200ng of template DNA. The 
primers used have the following sequences:  
5’-ACTATAAAACCATGAGAACCAC-3’ (forward primer) and  
5’-CCTCATCTTGGTTGGTCTTGC-3’ (reverse primer). The primers were 
synthesized by Inqaba Biotec, and were dissolved in Tris-EDTA consisting of 10 
mM Tris and 1.0 mM EDTA. 
The amplification consisted of predenaturation at 94oC for 5 minutes, followed by 
35 cycles of denaturation at 94oC for 30 seconds, annealing at 55oC for 45 seconds 
and extension at 72oC for 60 seconds, followed by final extension at 72oC for 5 
minutes. The presence of the desired product was checked on 1% agarose gel in 
TBE buffer at 70V for 45 minutes. The 645 bp PCR product was purified and 
sequenced in both directions by Inqaba Biotec. Sequencing primers used have the 
following sequences:  
5’-CATGAGAACCACTGCCATTG-3’ (forward) and  
5’-CTTGCCTCTGGAAGAGCAG-3’ (reverse). Sequences were aligned with the 
haptoglobin reference sequence from GeneBank using computer software 
Sequencher™ 4.0.  
 
2.4 Alternative methods for detecting single nucleotide polymorphism 
Allele-specific amplification (ASA) was used for the detection of single 
nucleotide polymorphism (SNP) found by direct sequencing, which is applicable 
to a large number of samples and less expensive than direct sequencing.  
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The method uses one set of primers for each allele of the single nucleotide 
polymorphism (Okayama et al, 1989). The primers are designed such that the 3'-
end of one primer in a primer set matches allele A, and another primer in the other 
set with the 3'-end matching B allele (Fig 2.1). Homozygous samples for A (or B) 
will yield a PCR product only with A-specific (or B-specific) primer. 
Heterozygous samples (AB) will yield a product with both primers. PCR was ran 
at stringent annealing temperatures for specific binding (Okayama et al, 1989). 
The ASA was optimized by using samples with known nucleotide sequences. A 
control was included during optimization in order to conclude with certainty that 
the PCR amplification was allele-specific under those amplification conditions. 
For the -295T allele, optimization did not include a control as only TT and TC 
genotypes were found by direct sequencing. In that case, the amplification was 
done at the highest possible annealing temperature. 
Based on the polymorphisms obtained by direct sequencing, allele-specific 
primers for the four most common polymorphisms were designed (Fig 2.1).  PCR 
was carried out in a 20 µl reaction volume containing 1.25 units of Taq 
polymerase, 200 µM of dNTPs, 1.5 mM MgCl, 0.2 µM of each of the primers and 
1 µg of template DNA. The thermocycling procedure consisted of predenaturation 
at 94°C for 5 minutes, 35 cycles of denaturation at 94°C for 1 min, annealing for 
45 seconds at different temperatures due different GC contents (Table 2.1) and 
extension at 72°C for 1 minute,  followed by a final extension at 72°C for 7 min. 
The presence of the PCR products was verified on 1 to 1.7% agarose gels, 
depending on the size of the expected fragment. Electrophoresis was carried out in 
TBE buffer for 45 minutes at a constant voltage of 75V. The gels were then  
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visualised  under the UV light using the image analyser. 
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                        ASA Fw 
-695 ctagtacctgggatacacacaggtgc 
-671 agacatttgactgagacatattgatttttctcatctgcctatttaggctaatcaccag 
              PCR Fw 
-611 actataaaaccatgagaaccactgccattgagtatagtctgtgtcagtctacactatagc 
                                Seq Fw 
-551 tttaactagttgtgtgatttcttgcaaagagcaatcagagaagacacaataaacacattt 
      
-491 actgatttcaggctggagagcttttaagcaatagggagatggccacacacaaggtggaga 
      
-431 aaattactgtgaaaaggaagtactttctttagagccccacctaagctaggctgcagaaat 
      
-371 gtctacaatgggtttgaaaaaactcaaaatgagcctttctgcagtgtgaaaatcctccaa 
           -295C Fw           -295T Rv 
-311gataaagagacagac/ttgatggttcctgccgccgccctgtcctgcccagttgctgatttca 
      
-251 ggaaatactttggcaggtttgtgggtcatagagttgccaggtttcttgggatttgtaata 
      
-191 gaacatcacaagaaaatcaagtgtgaagcaagagctcaactcttaacaggggtattgttt 
                  -104T Fw              -104A Rv 
-131gtggttttgttactggaaaagatagt/agaccttaccagggccaaagtttgtagacacagga 
                                                     
-71     
attacgaaa/ctggaga/gagggggagaagtgagctagtggcagcataaaaagaccagcagatg 
   -61C Fw                    -55G Rv 
                        +1                   PCR Rv 
 -9   ccccacagcactgctcttccagaggcaagaccaaccaagatgaggtgggtccacagcttt                       
                       Seq Rv 
                                         ASA Rv 
 52   ccctcctgcctttcctctggttctttatttcagtcttttttgca 
 
Fig 2.1. Nucleotide sequence of the promoter region of the haptoglobin gene. The 
arrows show the binding sites of the primers and the directions in which they 
extend. The nucleotide bases in bold are the single nucleotide polymorphisms. 
 
 
-55A Rv -61A fw 
Rv 
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Table 2.1. Primer set sequences used in ASA, annealing temperatures for the 
primers and sizes of the products.  The nucleotide bases in bold at the 3´-end are 
allele-specific.  
Primer 
name  
Primer sequence SNP Annealing 
temp 
Product 
size 
-295T Rv 
ASA Fw 
5’GCGGCGCAGGAACCATCAA-3’ 
5’-CCTGGGATACACACAGGTGC -3’ 
-295T/C 68oC 416 bp 
-295C Fw, 
PCR Rv  
5’-TCCAAGATAAAGAGACAGAC-3’ 
5’-CTTGCCTCTGGAAGAGCAG-3’ 
-295T/C 56oC 350 bp 
-104A  Rv 
Seq Fw 
5’-CTTTGGCCCTGGTAAGGTCTT-3’ 
5’- CATGAGAACCACTGCCATTG -3’ 
-104A/T 60 oC 517 bp 
-104T Fw 
ASA Rv 
5’-TTGTTACTGGAAAAGATAGT-3’ 
5’- AAAGACTGAAATAAAGAACCA 3’ 
-104A/T 55oC 212 bp 
-61A Fw 
ASA Rv 
5’-TAGACACAGGAATTACGAAA-3’ 
5’- AAAGACTGAAATAAAGAACCA - 3’ 
-61A/C 54.4oC 168 bp 
-61C Fw, 
ASA Rv 
5’-TAGACACAGGAATTACGAAC -3’ 
5’- AAAGACTGAAATAAAGAACCA -3’ 
-61A/C 60oC 168 bp 
-55A Rv 
Seq Fw 
5’-CTAGCTCACTTCTCCCCCTT-3’ 
5’- CATGAGAACCACTGCCATTG -3’ 
-55A/G 60 oC 547 bp 
-55G Rv 
Seq Fw 
5’-CTAGCTCACTTCTCCCCCTC-3’ 
5’- CATGAGAACCACTGCCATTG -3’ 
-55A/G 61 oC 547 bp 
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2.5. Protein polymorphism  
2.5.1 Haptoglobin genotype determination 
Exploiting the known size difference between Hp1 and Hp2 alleles (Fig 2.2), 
specific alleles were amplified by PCR with one pair of primers (Koch et al, 
2002). The primers used were 5'-GAGGGGAGCTTGCCTTTCCATTG-3' (primer 
A) and 5'-GAGATTTTTGAGCCCTGGCTGGT-3' (primer B). The primers bind 
to sites that are not specific to the alleles, upstream and downstream of the allele-
specific regions (Fig 2.2). 
Depending on the genotype presented by the template, an Hp1/Hp1 product of 
1757 bp, a 3481 bp product of Hp2/Hp2, or both bands in Hp2/Hp1 were generated 
by PCR using primer set AB. In most cases, the Hp2-specific 3481 bp product was 
very faint or invisible in the presence of the 1757 bp band. In such cases another 
set of primers, CD, was used to amplify a 349 bp Hp2 allele-specific sequence to 
verify the absence of the 3481 bp product (Fig 2.2). The primers have the 
following sequences: 5'-CCTGCCTCGTATTAACTGCACCAT-3' (primer C) and  
5'-CCGAGTGCTCCACATAGCCATGT-3' (primer D). The primers were 
synthesized by Inqaba Biotec and were diluted in TE. PCR was carried out in a 20 
µl reaction volume containing 1.25 units of Taq polymerase, 200 µM of dNTPs, 
1.5 mM MgCl, 0.2 µM of each of the primers and 1 µg of template DNA. After 
initial denaturation at 95°C for 2 min, the thermocycling procedure consisted of 
denaturation at 95°C for 1 minute, annealing 69°C for 2 min and extension at 
69°C for 2 min, repeated for 35 cycles, and followed by a final extension at 72°C 
for 5 min (Koch et al, 2002). The PCR products were separated on 1% agarose gel 
containing 0.5 µg/ml ethidium bromide in TBE buffer at 70V for 1 hour.  
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Fig 2.2. Structure of haptoglobin alleles Hp1 and Hp2. The arrows show the 
direction in which the primers extend. The letters A, B, C and D are the names of 
the primers; they show the sites where they bind (Koch et al, 2002) 
 
2.5.2 Phenotype determination 
The haptoglobin genotypes were confirmed by phenotype determination. The 
plasma samples were first treated with nevirapine (0.02mg/L) to deactivate any 
HIV that might be in the samples. Haptoglobin phenotypes were determined from 
12 µl of haemoglobin-enriched plasma by polyacrylamide gel electrophoresis 
(PAGE) followed by peroxidase staining (Linke, 1984; Koch et al, 2002). The 
haemoglobin stock solution (10%) was prepared from an HIV negative sample. 
After the removal of plasma, the blood sample was spun at 2500 rpm for 10 
minutes. The sedimented blood cells were washed five times, each time in 10 ml 
of phosphate buffer saline (PBS) containing 0.1 M sodium phosphate and 0.075 M 
Exon 3 Exon 4 
A   
  
D 
  1757 bp 
B   C 
Hp1 
   Exon 3 Exon 6 Exon 5 Exon 4 
  3481 bp 
 A 
  
C 
  
D 
  
D   
 C 
  
B 
349 bp 
1724 bp 1711 bp 
1711 bp 
Hp2 
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NaCl, pH 7.2. One millilitre of packed cells was lysed for 30 minutes with 9 ml of 
distilled water. The solution was centrifuged at 10 000 g for 1 hour, and the 
supernatant (haemoglobin solution) was kept in aliquots at -70oC. Ten microliters 
of plasma was mixed with 2 µl of 10% haemoglobin solution, and the samples 
were incubated at room temperature for 5 minutes to permit haptoglobin-
haemoglobin (Hp-Hb) complexes to form. An equal volume of sample buffer 
containing 0.125 mol/L Tris (pH 6.8), 200 g/L glycerol and 0.01g/L bromophenol 
blue was added to each sample before loading and electrophoresis. The Hp-Hb 
complexes were resolved by electrophoresis on continuous 4.7% polyacrylamide 
gel in Tris-Borate buffer containing 0.05 M Tris and 0.023 M boric acid, pH 8.7, 
using Tris-Borate buffer. Electrophoresis was performed at a constant voltage of 
250 for 2.5 hours.  
After electrophoresis, the Hp-Hb complexes were visualised by soaking the gel in 
the fresh peroxidase staining solution containing 0.14 M phosphate –citrate buffer, 
0.3% guaiacol and 0.03% hydrogen peroxide for about 15 minutes. 
 
2.6. Data analysis 
2.6.1. Determination of allele and genotype frequencies 
Genotype and allele frequencies were determined by gene counting. This was 
done by counting the total number of each genotype and allele in the population, 
and determined the proportion of each in the population (Hartl and Clark, 1989). 
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If x, y and z respectively mean the number of individuals carrying AA, AB and 
BB genotypes in a population, and the total sample size is n, then:               
 
 
                                        Frequency of AA = x       
                                                                        n 
    
                                        Frequency of BB = y 
                                                                       n 
      
                                        Frequency of AB = z          
                                                                       n   
 
 
The A and B alleles’ numbers in the population were deduced from the number of 
individuals carrying genotypes AA, AB and BB, and the frequencies were 
calculated:     
Number of A alleles = 2x + y 
Number of B allele = 2z + y   
The total number of alleles is 2n because each individual carries two alleles, then: 
                                    A freq = 2x + y  = p 
                                                     2n                    
 
                                    B freq = 2z + y = q 
                                                    2n 
 
 
2.6.2. Hardy-Weinberg equilibrium 
To determine whether the population was in Hardy-Weinberg equilibrium, 
expected and observed genotypes numbers were compared. The expected 
genotypes numbers were calculated from allele frequencies using the Hardy-
Weinberg equation: p2 + 2pq +q2 = 1 
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If the population is in Hardy-Weinberg equilibrium, AA, AB and BB frequencies 
would be p2, 2pq and q2 respectively (Crow, 1986; Hartl and Clark, 1989).  
The observed and the expected numbers were compared using the chi-squared (χ2) 
test:  
                                                χ
2
 = Σ (o-e)2 
                                                                                            e 
    
 where o =  observed number 
               e = expected number. 
 
The χ2 test determines whether observed numbers are significantly different from 
the expected numbers (Crow, 1986). A P value of below 0.01 was considered to 
indicate a lack of significant deviation from the predicted Hardy-Weinberg 
distribution. 
 
2.6.3. Linkage equilibrium and disequilibrium 
Linkage disequilibrium measures association of specific alleles at different loci on 
the same chromosome (Nei, 1987). Pairwise linkage disequilibrium was analysed 
using a computer program called Linkage Disequilibrium Analyzer (LDA) version 
1.0 (Keyue et al, 2003).  
 
 
 If there are two alleles on the same chromosome:  
             Allele 1                           A1                   B1 
             Allele 2                           A2                   B2 
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Let the allele frequencies of A1, A2, B1 and B2 be y1, y2, y3 and y4, respectively.  
The possible genotypes are A1B1, A1B2, A2B1 and A2B2. If x1, x2, x3 and x4 are the 
frequencies of these genotypes, respectively, then: 
 The frequency of gametes that carry A1 =  x 1 + x2 
 The frequency of gametes that carry B1 =  x1 + x3 
 The frequency of gametes that carry A2 =  x3 + x4 
 The frequency of gametes that carry B2 =  x2 + x4 
Linkage disequilibrium was calculated using the formula that compares the 
gametic frequency with the product of allele frequencies (Nei, 1987; Hartl and 
Clark, 1989): 
                                                   D = x1 – y1y3  
Where x1 = A1B1 frequency, y1 = A1 frequency and y3 = B1 frequency. 
If D > 0, allele A1 is associated with B1 and A2 with B2  
If D = 0, different alleles are randomly associated at different loci, and the alleles 
are in linkage equilibrium 
If D < 0, A1 is associated with B2 and A2 is associated with B1 (Nei, 1987; 
Lewontin, 1988; Hartl and Clark, 1989).  
 
The degree of the non-random association of the alleles was measured using the 
formula:  
                                    D´ = D__ 
                                            Dmax 
 
where D = linkage disequilibrium, Dmax is the largest value D can take with given 
marginals (Nei, 1987; Lewontin, 1988; Hartl and Clark, 1989). 
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The largest value D can be is either y1y4 or y2y3, while the most negative value can 
be either y1y3 or y2y4, thus: 
                                            Dmax = min (y1y3, y2y4) when D<0 
                                                                and          
                                             Dmax = min (y1y4, y2y3) when D>0 
 
The value of D´ ranges between -1 and 1 (Lewontin, 1988). 
      
2.6.4. Haplotype analysis 
A haplotype is a set of SNP alleles along a region of a chromosome. If a 
chromosome has two SNP alleles, A/G and C/T, the four possible haplotypes for 
these alleles are AC, AT, GC and GT (Tregouet et al, 2004). Haplotypes and 
haplotype frequencies were determined using Arlequin version 2.000 software 
which implements expectation maximization (EM) algorithm (Schneider et al, 
2000).  
 
2.6.5 Determination of genotype and phenotype /disease status association     
To examine whether variation in the coding and noncoding regions of the 
haptoglobin gene are associated with susceptibility to infection by HIV and TB, 
and the rate of HIV/AIDS disease progression, the study population was divided 
into groups and subgroups.  
For susceptibility to HIV and TB, the study population was divided into: 
(i) HIV positive and general population (with unknown HIV status)  
(ii) With TB and without TB. 
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To examine whether the polymorphisms have an impact on the rate of HIV/AIDS 
disease progression, the HIV positive group was divided into the following 
groups: 
(i) A group that was diagnosed with HIV 5 years or less prior to the 
collection of the samples and were symptomatic and the group that had 
been HIV positive for more than 5 years and were asymptomatic 
(ii) A group that was diagnosed with HIV 5 years or less prior to the 
collection of the samples and had a CD4+ cell count of ≤200 cells/ml3 
and the group that had been HIV positive for more than 5 years and 
had  a CD4+ cell count of greater than 200 cells/ml3. 
(iii) Rapid progressors (those who were diagnosed with HIV 5 years or less 
prior the collection of the samples and were symptomatic) and the 
long-term nonprogressors (those who had been living with the virus for 
8 to 14 years). 
Frequencies of genotypes and phenotypes were determined amongst the 
subgroups. Because of the small values in the subgroups, Fisher’s exact test 
was used to determine whether the numbers between the subgroups differed 
significantly. The Fisher's exact test procedure calculates an exact probability 
value for the relationship between two variables (Sokal and Rohlf, 1981; 
Rosner B, 1990). Statistical Analysis System (SAS) software was used to 
perform the Fisher’s exact test.   
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2.7.6 Haplotype/Disease status association 
We examined whether haplotypes of the haptoglobin gene have an impact on 
susceptibility to HIV and TB infection. The study population was categorized as 
in section 2.7.5. Haplotype frequencies between the subgroups were determined 
using Arlequin software, and compared between the subgroups. Statistical 
Analysis System (SAS) software was used to perform the Fisher’s exact test. 
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CHAPTER 3 
RESULTS 
 
3.1. Direct sequencing 
Sequencing of both strands of the 645 bp fragment of the promoter region (Fig 
3.1) showed polymorphism at six sites (Fig 3.2), which resulted in 34 different 
sequences in 52 samples from 42 HIV positive subjects and 10 subjects with 
unknown HIV status. In addition to the four previously known base substitutions, 
i.e., -55A/G, -61A/C, -104T/A (Maeda, 1991; Teye et al, 2003) and -242T/C 
(Teye et al, 2003), two which were not reported previously were found at 
positions -103 and -295. The polymorphisms were G/T and T/C, respectively.  
None of the individuals was homozygous for C at position -295; only -295TT and 
TC were found.  Homozygous genotypes TT for polymorphisms -103G/T and -
242C/T were not found. At position  -61, only one individual was C homozygous.  
Genotype and allele frequencies for all the polymorphic sites were determined 
(Table 3.1.1).  As in Ghanaians, -242T/C occurred at a very low frequency (0.02) 
in the study population. The polymorphism at site -103 was rare as well, with 
frequency of 0.02. The C alleles at sites -61 and -295, respectively, were found at 
low frequencies in the population: 0.15 and 0.11 respectively.   
The χ2 test for goodness of fit showed that the population did not deviate 
significantly from the expectations of the Hardy-Weinberg equilibrium at any of 
the six sites (Table 3.1.1). 
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 Fig 3.1.1. An agarose gel of the 645 bp promoter region. In lane 1 is a molecular 
weigh marker VI.                     
 
 
                          -295*              -242 #                     -104 -103* #              -61      -55 
 
 
 
                          C/T                  C/T                       T/A  G/T                  A/C      A/G 
 
Fig 3.1.2. Schematic diagram showing locations of the six SNPs found by direct 
sequencing of the 645 bp fragment of the upstream noncoding region of the 
haptoglobin gene.  The new ones are indicated by *, the ones that occur at low 
frequencies in the population are indicated by #. 
 
 
 
 
 
   1     2      3     4     5 
645 bp 
500 bp 
  750 bp 
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Table 3.1.1. Genotype and allele frequencies for the 6 polymorphic sites found by 
direct sequencing and the χ2 test for the goodness of fit between the genotypes for 
each site. There was no significant deviation from the expectations of Hardy-
Weinberg equilibrium (P<0.01). 
Site Genotype n Genotype 
frequency 
Allele n Allele 
frequency 
χ
2 
1df 
-55 AA 18 0.35 A 57 0.55  
 
AG 21 0.40     
 
GG 13 0.25 G 47 0.45  
Total  52   104  1.80 
 
       
-61 AA 37 0.71 A 88 0.85  
 
AC 14 0.27     
 
CC 1 0.02 C 16 0.15  
Total  52   104  0.09 
 
       
-103 GG 51 0.98 G 103 0.99  
 
TG 1 0.02     
 
TT 0 0.00 T 1 0.01  
Total  52   104  0.00 
 
       
-104 AA 6 0.11 A 35 0.34  
 
AT 23 0.44     
 
TT 23 0.44 T 69 0.66  
Total  52   104  0.005 
 
       
-242 CC 51 0.98 C 103 0.99  
 
TC 1 0.02     
 
TT 0 0.00 T 1 0.01  
Total  52   104  0.00 
 
       
-295 TT 41 0.79 T 93 0.89  
 
TC 11 0.21     
 
CC 0 0.00 C 11 0.11  
Total  52   104  0.73 
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3.2. Allele-specific amplification 
Allele-specific amplification was applied to a large population to detect the four 
most common SNPs found by direct sequencing.  The presence or absence of the 
PCR product is dependent on the allele or genotype presented by the DNA 
template. Samples homozygous for a certain allele yielded a product in the 
presence of the primer specific for that allele, and not with the other allele-specific 
primer. Heterozygous samples gave products with both sets of primers. The sizes 
of PCR products for different alleles are shown in figures 3.2.1, 3.2.2, 3.2.3 and 
3.2.4.   
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Fig 3.2.1. An agarose gel showing allele-specific PCR products for the -55A/G 
polymorphism. Lanes 2-4 show -55A allele-specific product, lanes 4-7 show -55G 
allele-specific product. The PCR products are of the same size (547 bp) for both 
alleles because the allele-specific primers differ by one nucleotide base at the 3'-
end, they extend in the same direction and they were used with the same allele-
nonspecific forward primer. The reactions for each allele were done separately 
(Fig 2.1). The samples were run against 100bp molecular weight marker (lane 1). 
Samples which are genotype -55AA produced a -55A allele PCR products only, -
55GG samples gave -55G allele PCR products only, and heterozygous samples 
yielded a product with both allele-specific reactions. 
                                          
   1      2     3     4     5    6    7 
 
100 bp 
  500 bp 
547 bp 
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Fig 3.2.2. A 1.7% agarose gel showing PCR products of allele-specific 
amplification for -61A (lanes 2-4) and -61C (lanes 5-7) alleles run against a 100 
bp molecular weight marker (lane 1). The size of the product was 168 bp for both 
alleles because the allele-specific primers differ by one nucleotide base at the 3'-
end, they extend in the same direction and they were used with the same allele-
nonspecific forward primer. The reactions for each allele were done separately 
(Fig 2.1). Samples which were homozygous for A yielded a -61A allele product 
only, homozygous C yielded a -61C allele product only. Heterozygous samples 
showed PCR products in both reactions.   
          
   1      2     3      4      5       6      7 
168 bp 
3000 bp 
  500 bp 
  200 bp 
       100 bp 
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Fig 3.2.3. An agarose gel showing allele-specific PCR products for the A/T 
polymorphism at site -104. Allele T was characterized by a 212 bp PCR product 
(lanes 2-4). Allele T was characterized by a 517 bp PCR product (lanes 5-7). The 
samples were run against the 100 bp ladder (lane 1). Samples which were 
homozygous for genotypes AA and TT yielded 212- and 517-bp bands, 
respectively.   The AT genotype was characterized by the presence of both the 
212- and 517-bp products.    
 
 
 
 
 
 
 
 
   1      2     3      4      5       6      7 
100 bp 
500 bp 
200 bp 212 bp 
517 bp 
3000 bp 
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A                                                              B 
                                                              
                                                                         
                                                             
 
Fig 3.2.4. An agarose gel showing allele-specific PCR products for -295T (A) and      
-295C (B) alleles. The TT genotype gave a 416 bp PCR product (A, lanes 2 and 
3), the CC genotype gave a 350 bp product (B, lanes 1 and 2), and the 
heterozygote TC was distinguished by the presence of both 416 and 350 bp PCR 
products. 
 
 
3.2.1. Genotype and allele frequencies 
 
Genotype and allele frequencies in the whole study population were determined, 
and the χ2 test demonstrated that the population did not deviate significantly from 
the expectations of the Hardy-Weinberg equilibrium at any of the four sites at 
P<0.01 (Table 3.2.1). 
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Table 3.2.1. Genotype and allele frequencies for the four common polymorphisms 
in the whole study population and the χ2   test. 
 
 
3.3. Protein polymorphism 
Polymorphism in the protein coding region of the haptoglobin gene was 
determined by amplifying allele-specific fragments according to Koch et al 
(2002). The genotypes were then confirmed by phenotype determination on 
polyacrylamide gel.    
 
3.3.1 Haptoglobin protein polymorphism genotype determination 
In PCR, primer set AB gave 1757- and 3481-bp products for Hp1-1 and Hp2-2 
genotypes, respectively. Heterozygote genotype Hp2-1 was characterized by the 
presence of both 1757 and 3481 bp bands (Fig 3.3.1.1 A). In some cases, it was 
Site  Genotype n Frequency Allele n Allele 
frequency 
χ
2  
1df 
-55 AA 66 0.30 A 243 0.56  
 
AG 111 0.52     
 
GG 38 0.18 G 187 0.43  
Total  215   430  0.51 
 
       
-61 AA 178 0.83 A 392 0.91  
 
AC 36 0.17     
 
CC 1 0.005 C 38 0.09  
Total  215   430  0.53 
 
       
-104 AA 42 0.19 A 183 0.43  
 
AT 99 0.46     
 
TT 74 0.34 T 247 0.57  
Total  215   430  0.70 
 
       
-295 TT 134 0.62 T 341 0.79  
 
TC 73 0.34     
 
CC 8 0.04 C 89 0.21  
Total  215   430  0.17 
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not possible to determine with certainty the presence of the 3481-bp Hp2-specific 
band in Hp2-1 samples. In such cases, primer set CD was used to confirm the 
presence or absence of Hp2 band in the samples that produced a 1757-bp band 
with primer set AB. Hp2-1 genotype gave a 349-bp Hp2-specific band in the 
presence of primer set CD (Fig 3.3.1.1 B). Genotype and allele frequencies were 
calculated. The Hp2-1 genotype occurred at a high frequency, 0.567. The 
homozygous genotypes occurred at fairly similar frequencies: 0.22 and 0.21 for 
Hp1-1 and Hp2-2, respectively.  The Hp1 and Hp2 allele frequencies were fairly 
similar in the population, 0.502 and 0.498, respectively (Table 3.3.1.1).  The χ2 
test illustrates that the population does not deviate significantly from the 
expectations of Hardy-Weinberg equilibrium (P<0.01).  
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A.                                                                               B. 
 
Fig 3.3.1.1. Hp1 and Hp2 allele-specific PCR products.  (A) Depending on the 
genotype presented by the template, an Hp2-2 product of 3481bp (lanes 2 and 3), 
a 1757bp band of Hp1-1 (lane 4) or both bands in Hp2-1 were amplified (lane 1) 
using primer set AB. Lane 5 is a molecular weight marker. (B) A 349bp product 
of primer set CD yielded by Hp2-1 samples in the confirmation of the absence or 
presence of the Hp2-allele-specific fragment. In lane 1 is a 100bp molecular 
weight marker ladder. 
                                                  
 
 
 
 
 
 
349 bp 
400 bp 
2000 bp 
1757 bp 
3481 bp 
  1        2       3      4   1        2       3      4       5 
3000 bp 
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Table 3.3.1.1. Genotype and allele frequencies of the coding region in the whole 
study population.  
Genotype n  Genotype 
frequency 
Allele n Allele 
frequency 
χ
2 
1df 
Hp1-1 47 0.22 Hp1 216 0.50  
Hp2-1 122 0.57     
Hp2-2 46 0.21 Hp2 214 0.50  
Total 215   430  3.65 
 
 
3.3.2 Phenotype determination 
Polyacrylamide gel electrophoresis of plasma gave a band pattern that 
differentiated between Hp1-1, Hp2-1 and Hp2-2 protein phenotypes (Fig 3.3.2.1). 
Samples which are phenotypically Hp0 were identified by showing no protein 
bands on the polyacrylamide gel. The Hp1-1 phenotype was characterized by a 
single fast-migrating band, Hp2-2 by a series of slow-migrating bands, Hp2-1 by 
the presence of both slow- and fast-migrating bands (Fig 3.3.2.1).  
The proportion of each phenotype in the whole study population was determined. 
Hp0 phenotype occurred at the frequency of 0.303 (Table 3.3.2.1). This frequency 
is in accordance with findings of Constants et al (1981), who found that in Sub-
Sahara Africa the frequency of the Hp0 phenotype is between 10 to 40%.  
The Hp0 phenotype was not exclusively found in one genotype, but distributed 
among all three genotypes, Hp1-1, Hp2-1 and Hp2-2. The Hp1-1 and Hp2-1 
genotypes were found in equal frequencies in Hp0 individuals (0.42). This 
difference in frequencies was statistically significant (P=0.0001) (Table 3.3.2.2).  
Among the polymorphisms of the promoter region, the Hp0 phenotype was most 
common in individuals who carried a -55GG and -104AA genotypes. The 
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frequency difference was statistically significant for both polymorphic sites 
(P<0.05). Previous studies have reported -61C allele to be a cause of Hp0 
phenotype in Africans (Teye et al, 2003). In this study, there was only one 
individual who was homozygous for this allele. The individual was Hp0.  
 
 
 
 
Hp2 bands 
 
 
 
   
 
 
 
 
 
Fig 3.3.2.1. Haptoglobin phenotypes on the polyacrylamide gel. The band pattern 
distinguished between the phenotypes. Hp1-1 showed a single fast-moving band 
(lane 2). Hp2-2 was characterized by a series of slow-moving bands (lane 4). Hp2-
1 phenotype showed both Hp1 and Hp2 bands (lanes 1 and 3). 
 
 
 
 
 
 
 
1             2              3               4 
   
 
Hp1 band 
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Table 3.3.2.1. Haptoglobin phenotype distribution in the whole study population.                                      
                                                         
                                                 
Phenotype n Phenotype 
frequency 
Hp0-0 43 0.30 
Hp1-1 12 0.08 
Hp2-1 64 0.45 
Hp2-2 23 0.16 
     Total 142  
 
 
Table 3.3.2.2. Genotype distribution in Hp0 phenotype and the other phenotypes 
 
Hp0 (n=42) With Hp protein (n=100)  P 
Promoter 
region 
Genotype n Freq  n Freq   
-55 AA 6 0.14  32 0.34  0.002 
 
AG 18 0.43  54 0.54  
 
 
GG   18 0.43  14 0.14   
 
        
-61 AA 35 0.83  86 0.86  0.426 
 
AC 6 0.14  14 0.14   
 
CC 1 0.02  0 0  
 
 
        
-104 AA 16 0.38  12 0.12  0.0005 
 
AT 20 0.48  52 0.52   
 
TT 6 0.14  36 0.36   
 
       
 
-295 TT 25 0.59  57 0.57  0.853 
 
TC 15 0.36 
 
38 0.38 
 
 
 
CC 1 0.02 
 
5 0.05   
 
   
 
    
Coding 
region 
Genotype   
 
    
 
Hp1-1 18 0.43 
 
11 0.11  0.0001 
 
Hp2-1 18 0.43 
 
68 0.68   
 
Hp2-2 6 0.14 
 
21  0.21   
 
P = Fisher’s probability  
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3.4. Distribution of haptoglobin alleles in Black South African ethnic groups 
In our study population of 136 Black South Africans with information on family 
origin, some groups were represented by sample sizes too small for frequency 
distribution analysis. Venda and Ndebele groups were each represented by one 
individual, Swazi group by 5 individuals (Table 3.4.1). Twenty five percent of the 
individuals in the study population had parents or grandparents from different 
ethnic groups, or from outside South Africa.  
The frequency of Hp1 allele in Zulu and Sotho groups was lower than the 
previously reported frequencies, while in Tswana and Tsonga groups it was higher 
(Table 3.4.1) (Nurse et al, 1974).  The allele distribution in Xhosa and Pedi groups 
was in accordance with values published (Jenkins, 1972; Nurse et al, 1974).  The 
frequencies in Zulu, Xhosa and Tswana groups were similar. The allele’s 
distribution in Pedi and Tsonga groups showed very similar frequencies. The 
Southern Sotho group showed a very low Hp1 frequency, lower than the reported 
frequency (Nurse et al, 1974). These distributions are comparable to the ones 
previously published (Nurse et al, 1974), where Zulu, Swazi, Xhosa, Tswana and 
Sotho groups showed very similar frequencies. 
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Table 3.4.1. Hp1 allele distribution in South African ethnic groups.  
Ethnic group n Hp1 frequency 
Zulu 60 0.47 
Xhosa 16 0.50 
Pedi 11 0.59 
Tswana  19 0.53 
Sotho 14 0.43 
Tsonga 9 0.60 
                            
 
3.5. Association of genotypes and phenotypes with HIV/AIDS disease status  
Even though the size of the HIV positive population was 163, there were only a 
few subjects with usable clinical data for studying association between the rate of 
the disease progression and the haptoglobin gene polymorphism.  Thirty percent 
of the samples collected from Johannesburg General Hospital were collected from 
individuals who were diagnosed with HIV infection between the years 2000 and 
2003, and they were still asymptomatic at the time of sample collection. Sixty 
three samples from the NICD had no dates of diagnosis. However, these samples 
were useful in studying susceptibility to infection by HIV.   
Genotype and phenotype frequencies were determined and compared between the 
HIV positive population and the general population, between a TB+ and TB- 
groups, and between the groups defined by fast and slow rate of the disease 
progression. 
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3.5.1.1. Genotype and phenotype distribution in HIV positive and the general 
populations 
Neither the HIV positive population nor the general population deviated 
significantly from Hardy-Weinberg equilibrium at all the four polymorphic sites 
of the promoter region at significance level P<0.05 (Table 3.5.1.1). There was 
significant difference between the HIV positive and the general population at only 
one site. A significant difference (P=0.04) was observed at site -61, with a higher 
frequency of AC genotype in the general population. No significant association 
was observed between any of the other polymorphisms and the risk of HIV 
infection. 
An excess of the heterozygous genotype Hp2-1 was observed in the HIV positive 
population. The frequencies of the homozygote genotypes were similar in the HIV 
positive population. The χ2 test showed no significant deviation from the 
expectations of Hardy-Weinberg in both the HIV positive and the general 
populations for haptoglobin coding region genotypes (P<0.01). There was no 
association between the haptoglobin genotypes or alleles and susceptibility to HIV 
infection.   
Hp0 phenotype occurred at a frequency of 0.43 in the general population, and 0.25 
in the HIV positive population. These frequencies are in accordance with the 
findings of Quaye et al (2000), where the Hp0 phenotype was higher in HIV 
negative individuals than in the HIV positive individuals. Despite the difference in 
Hp0 phenotype frequency distribution observed in HIV positive and the general 
populations, the Fisher’s exact test showed no significant difference between the 
distribution of the four phenotypes in these two populations (Table 3.5.1.1).  
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Table 3.5.1.1. Genotype and phenotype distribution among HIV positive and 
general populations.  
 HIV positive General population P 
Promoter 
region 
Genotype n Freq χ21df   n Freq χ2 1df  
-55 AA 53 0.32 0.03 13 0.25 1.246 0.551 
 
AG 81 0.50  30 0.58  
 
 
GG   29 0.18  9 0.17   
 Total  163   52    
 
        
-61 AA 140 0.86 0.01 38 0.73 1.36 0.045 
 
AC 22 0.13  14 0.27   
 
CC 1 0.01  0 0.00  
 
Total  163   52    
 
        
-104 AA 36 0.22 0.90 6 0.12 0.18 0.212 
 
AT 74 0.45  25 0.48   
 
TT 53 0.33  21 0.40   
Total  163   52    
 
       
 
-295 TT 104 0.64 0.23 30 0.58 3.7 0.118 
 
TC 51 0.31 
 
22 0.42 
 
 
 
CC 8 0.05 
 
0 0.00   
Total  163   52    
  
  
 
 
 
Coding 
region 
Genotype 
  
 
   
 
 
Hp1-1 35 0.21 4.81 12 0.23 0.0 0.435 
 
Hp2-1 96 0.59  26 0.50  
 
 
Hp2-2 32 0.20  14 0.27   
Total      163   52    
       
Protein Phenotype      
 
Hp0-0   25 0.25 18 0.43 0.169 
 
Hp1-1  9 0.09 3 0.07  
 
Hp2-1  50 0.50 14 0.33  
 
Hp2-2  16 0.16 7 0.17  
Total         100                  - 42                    -  
 
P = Fisher’s probability 
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3.5.1.2. Haptoglobin polymorphism and the rate of the HIV/AIDS 
progression 
To determine whether the haptoglobin polymorphism has an impact on the rate of 
HIV/AIDS progression, phenotype and genotype frequencies were compared 
between the groups below, and the Fisher’s exact test was used to determine 
whether the frequencies differ significantly among the groups: 
(i) A group that was symptomatic 5 years or less prior the sample 
collection and the group that had been HIV positive for more than 5 
years and were asymptomatic (Table 3.5.1.2.1) 
(ii) Rapid progressors and long-term nonprogressors (Table 3.5.1.2.2). 
(iii) A group that was diagnosed with HIV 5 years or less prior the 
collection of the samples and had a CD4+ cell count of ≤200 cells/ml3 
and the group that had been HIV positive for more than 5 years and 
had  a CD4+ cell count of greater than 200 cells/ml3  (Table 3.5.1.2.3). 
 
The χ2 test showed none of the groups in all the categories deviated significantly 
from the expectations of the Hardy-Weinberg equilibrium at all the polymorphic 
sites of the promoter region at P<0.01.  
A high frequency of the genotype Hp2-1 was observed in both the symptomatic 
and asymptomatic groups. The symptomatic group did not deviate significantly 
from the expectations of Hardy-Weinberg equilibrium at P<0.01. The 
asymptomatic group showed a deviation from the Hardy-Weinberg equilibrium at 
P<0.01, and no deviation at P<0.001 (Table 3.5.1.2.1). Both groups in the other 
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two categories did not show a significant deviation from the expectations of 
Hardy-Weinberg equilibrium for the coding region polymorphism (P<0.01). 
The genotype and the phenotype frequencies did not differ significantly from each 
other in the symptomatic/asymptomatic groups, and the rapid progressors and the 
long-term nonprogressors. There was no significant difference between the 
genotype and phenotype distribution (Table 3.5.1.2.1; Table 3.5.1.2.2).   
 
In the CD4+cell depletion rate category, a statistically insignificant but noteworthy 
difference in frequency distribution between the groups was observed at site -104 
of the promoter region, the coding region and the phenotypes (Table 3.5.1.2.3).  
 At site -104, there was a high frequency of a heterozygous genotype AT in the 
group with a CD4+ cell count of below 200 (0.72) compared with 0.31 in the 
group with a count of more than 200 cells/ml3. The frequency of homozygote AA 
at the same site was considerably higher in the group with a CD4+ cell count of 
above 200 (0.38) than the group with a count of below 200 cells/ml3 (0.11).  
The frequency of Hp2-2 genotype was higher in the group with a count of below 
200 cells/ml3 (0.39) than Hp1-1 genotype of the same group (0.11), and higher 
than the frequency of Hp2-2 genotype in the group with a count of above 200 
cells/ml3 (0.15).  
The phenotype frequencies of Hp0 and Hp2-2 differed between the two groups. A 
high frequency of Hp0 phenotype was observed in the group with a CD4+ count of 
above 200 cells/ml3. This phenotype was found at a low frequency in the other 
group. Hp2-2 phenotype was higher in the group with a CD4+ count of below 200 
cells/ml3 and lower in the other group. The frequencies for Hp0-0 were 0.17 and 
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0.38 for the group with below and above 200 cells/ml3, respectively. For Hp2-2 
the frequencies were 0.39 and 0.15 for the group with a count of below and above 
200, respectively.  
The high frequency of Hp2-2 in the group with  the faster rate of CD4+ cell 
depletion is in agreement with previous studies where it was reported that Hp2-2 
is associated with a faster rate of CD4+ cell depletion (Quaye et al, 2000), and the 
rate of HIV/AIDS progression (Delanghe et al, 1996; Quaye et al, 2000). 
Although these frequency differences were statistically insignificant, further 
investigations need to be done on a larger population size with a more reliable 
clinical data.  
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Table 3.5.1.2.1. Genotype and phenotype frequencies between asymptomatic and 
symptomatic subjects five years after diagnosis with HIV infection. 
  ≤5yrs since diagnosis, 
symptomatic 
>5yrs since diagnosis, 
asymptomatic 
  P 
Promoter 
region 
Genotype n Freq χ2 1df n Freq χ2 1df  
-55 AA 5 0.26 0.05 6 0.22 0.04 1.000 
 
AG 9 0.47  14 0.52   
 
GG 5 0.26  7 0.26   
Total  19   27    
 
        
-61 AA 17 0.89 0.10 23 0.85 3.73 1.000 
 
AC 2 0.10  3 0.11   
 
CC 0 0.00  1 0.04   
Total  19   27   
 
        
-104 AA 4 0.21 0.05 7 0.26 0.03 1.000 
 
AT 10 0.53  13 0.48   
 
TT 5 0.26  7 0.26   
Total  19   27    
 
        
-295 TT 10 0.53 0.20 16 0.59 0.13 0.712 
 
TC 7 0.37  10 0.37 
 
 
 
CC 2 0.10  1 0.04 
 
 
Total  19   27    
  
    
 
Coding 
region 
Genotype 
     
  
 
Hp1-1 4 0.21 2.79 2 0.07 8.67 0.502 
 
Hp2-1 13 0.68  21 0.78   
 
Hp2-2 2 0.10  4 0.15   
Total  19   27    
    
 Protein Phenotype   
 
Hp0-0      5 0.26 9 0.33 0.575 
 
Hp1-1     3 0.16 1 0.04  
 
Hp2-1     9 0.47 14 0.52  
 
Hp2-2     2 0.10 3 0.11  
Total     19                   - 27                -  
P = Fisher’s probability 
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Table 3.5.1.2.2. Genotype and phenotype frequencies in rapid progressors and 
long-term nonprogressors 
  Rapid progressors Long-term nonprogressors    P 
Promoter 
region 
Genotype n Freq χ2 1df n Freq χ2 1df 
-55 AA 5 0.26 0.05 4 0.18 0.01 
 
AG 9 0.47  11 0.50  
 
GG 5 0.26  7 0.32  
Total  19   22   
 
       
 
 
0.845 
-61 AA 17 0.89 0.10 20 0.91 0.00 
 
AC 2 0.10  2 0.09  
 
CC 0 0.00  0 0.00  
Total  19   22   
 
       
1.000 
-104 AA 4 0.21 0.05 5 0.23 0.00 
 
AT 10 0.53  11 0.50  
 
TT 5 0.26  6 0.27  
Total  19   22   
 
       
1.000 
-295 TT 10 0.53 0.20 13 0.59 0.00 
 
TC 7 0.37  8 0.36  
 
CC 2 0.10  1 0.04  
Total  19   22   
0.893 
  
      
Coding 
region 
 
      
 
Hp1-1 4 0.21 2.79 2 0.09 6.57 0.599 
 
Hp2-1 13 0.68  17 0.77  
 
Hp2-2 2 0.10  3 0.14  
Total  19   22   
 
 
  
Protein Phenotype     
 
Hp0-0  5 0.26 9 0.35 0.645 
 
Hp1-1 3 0.16 1 0.07  
 
Hp2-1 9 0.47 10 0.45  
 
Hp2-2 2 0.10 2 0.13  
Total  19                     - 22                     -  
 
P = Fisher’s probability 
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Table 3.5.1.2.3. Phenotype and genotype distribution in groups with a CD4+ cell 
count of below and above 200 cells/ml3 five years after diagnosis 
 CD4+≤200, ≤5 yrs  
since diagnosis 
CD4+>200, > 5yrs  
since diagnosis 
  P 
Promoter 
region 
Genotype n Freq χ2 1df n Freq χ2 1df  
-55 AA 6 0.33 0.48 3 0.23 0.05 0.499 
 
AG 10 0.56  6 0.46  
 
 
GG   2 0.11  4 0.31   
Total  18   13    
 
        
-61 AA 16 0.89 0.10 12 0.92 0.00 1.000 
 
AC 2 0.11  1 0.08       
 
CC 0 0.00  0 0.00  
Total  18   13   
 
       
-104 AA 2 0.11 3.58 5 0.38 1.93 0.669 
 
AT 13 0.72  4 0.31  
 
 
TT 3 0.17  4 0.31   
Total  18   13    
 
        
-295 TT 11 0.61 0.02 7 0.54 1.19 0.832 
 
TC 6 0.33 
 
6 0.46 
 
     
 
CC 1 0.06  0 0.00  
Total  18   13   
  
  
 
 
Coding 
region 
Genotype       
 
Hp1-1 2 0.11 0.09 1 0.08 3.82 0.365 
 
Hp2-1 9 0.50  10 0.77  
 
 
Hp2-2 7 0.39  2 0.15   
Total    18   13    
 
 
    
Protein Phenotype     
 
Hp0-0  3 0.17   - 5 0.38      - 0.238 
 
Hp1-1 2 0.11  0 0.00  
 
 
Hp2-1 6 0.33  6 0.46   
 
Hp2-2 7 0.39  2 0.15   
Total  18      13        
 
P = Fisher’s probability 
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3.5.1.3. Genotype and phenotype frequencies in TB groups 
Both the TB+ and TB- groups did not show a significant deviation from the 
Hardy-Weinberg at any of the four polymorphic sites of the promoter region 
(Table 3.5.1.3).  
Excess of the Hp2-1 genotype was observed in both groups, and thus, deviation 
from the expectations of Hardy-Weinberg equilibrium at the statistical level 
P<0.001. The frequencies of the genotypes were comparable between the groups. 
Genotypes for all the polymorphic sites were comparable in the TB+ and TB- 
groups, and there was no significant difference between the two groups. These 
findings do not agree with the previous report on association of Hp2-2 with 
susceptibility to infection by TB (Fedoseeva et al, 1993), but are consistent with 
another study (Kasvosve et al, 1998) where the haptoglobin polymorphism was 
not associated with susceptibility to TB. 
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Table 3.5.1.3. Genotype and phenotype frequencies in groups with and without 
TB. 
 
 With TB Without TB    P 
Promoter 
region  
Genotype n Freq χ2 1df n Freq χ2 1df  
-55 AA 4 0.27  23 0.29  0.873 
 
AG 7 0.46  39 0.49   
 
GG   4 0.27  17 0.21   
Total  15  0.07 79  0.00  
 
        
-61 AA 14 0.93  67 0.85  0.733 
 
AC 1 0.07  11 0.14   
 
CC 0 0.00  1 0.01   
Total  15  0.00 79  0.59  
 
        
-104 AA 3 0.20  16 0.20  0.929 
 
AT 7 0.47  42 0.53   
 
TT 5 0.33  21 0.27   
Total  15  0.00 79  0.37  
 
        
-295 TT 10 0.67  47 0.59  0.901 
 
TC 4 0.26  27 0.34   
 
CC 1 0.07  5 0.06   
Total  15  0.42 79  0.18  
  
     
Coding 
region 
Genotype 
       
 
Hp1-1 3 0.20  10 0.13  0.502 
 
Hp2-1 11 0.73  55 0.70   
 
Hp2-2 1 0.07  14 0.17   
Total  15  4.41 79  11.83  
      
Protein Phenotype     
 
Hp0-0  5 0.33  20 0.25               0.815 
 
Hp1-1 1 0.07  8 0.10  
 
Hp2-1 8 0.53  38 0.48  
 
Hp2-2 1 0.07  13 0.16  
Total  15     - 79       - 
 
P = Fisher’s probability 
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 3.6. Haplotype analysis 
3.6.1 Haplotypes in the study population 
Haplotypes for all five polymorphic sites were analyzed using Arlequin software. 
The frequencies of the haplotypes for all five polymorphic sites were determined 
in the whole study population.  
A total of 32 haplotypes was found in 215 samples.  The most common haplotype 
in the 20 most common ones, Hap14, occurred at the frequency of 0.215 in the 
study population. Hap10, Hap 19 and Hap 20 were the least common haplotypes 
in the population, with frequencies that was between 0.002 and 0.003 (Table 
3.6.1).  
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Table 3.6.1. Haplotype frequencies in the study population 
Haplotype name                          Frequency                          Haplotype 
Hap 1 0.013 AAAC1 
Hap 2 0.035 AAAT1 
Hap 3 0.042 AAAT2 
Hap 4 0.007 AATC1 
Hap 5 0.063 AATC2 
Hap 6 0.183 AATT1 
Hap 7 0.139 AATT2 
Hap 8 0.011 ACAT2 
Hap 9 0.021 ACTC2 
Hap 10 0.003 ACTT1 
Hap 11 0.048 ACTT2 
Hap 12 0.047 GAAC1 
Hap 13 0.045 GAAC2 
Hap 14 0.215 GAAT1 
Hap 15 0.018 GAAT2 
Hap 16 0.023 GATC1 
Hap 17 0.028 GATT1 
Hap 18 0.054 GATT2 
Hap 19 0.002 GCTT1 
Hap 20 0.003 GCTT2 
          
 
 
3.6.2. Pairwise allelic linkage disequilibrium  
Pairwise allelic linkage analysis of the five polymorphic sites showed that all the 
alleles were nonrandomly associated (linkage disequilibrium). The specific 
associations were deduced from the value of D, whether it was positive or 
negative (Table 3.6.2.). The degree of nonrandom association was very strong 
between the haplotypes of -55/-61 and -61/coding region, 0.88 and 0.84, 
respectively. The haplotypes of -55/-104, -61/-104 and -61/-295 sites also showed 
strong linkage disequilibrium. The degree of nonrandom association was weak 
between the other haplotypes, with |D'| values of 0.46 and less (Kidd et al, 1998).  
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Table 3.6.2. Linkage disequilibrium between haptoglobin alleles. 
 
Sites D Specific 
associations 
|D'| Std 
deviation 
-55/-61 -0.42 -55G with -61A, 
-55A with -61C 
-0.88 0.03 
-55/-104  0.56 -55A with -104T, 
-55G with -104A 
 0.57 0.02 
-55/-295  0.22 -55G with -295C, 
-55A with -295T 
 0.31 0.02 
-61/-104 -0.32 -61A with -104A, 
-61C with -104T 
-0.69 0.02 
-61/-295 -0.16 -61A with -295C, 
-61C with -295T 
-0.73 0.03 
-104/-295  0.16 -104A with-295C, 
-104T with -295T 
 0.22 0.02 
-55/Coding region -0.41 -55A with Hp2, 
-55G with Hp1 
-0.46 0.01 
-61/ Coding region  0.48 -61A with Hp1, 
-61C with Hp2 
 0.84 0.03 
-104/Coding region -0.38 -104T with Hp2, 
-104A with Hp1 
-0.44 0.01 
-295/Coding region -0.19 -295T with Hp2, 
-295C with Hp1 
-0.31 0.01 
 
 
 
3.6.3. Haplotype/Disease status association 
Given our small sample size, the haplotype/disease status association 
determination was done on the three promoter region polymorphic sites that are 
found within the IL-6 response segment, sites -55, -61 and -104. The sites are 
close together and showed strong linkage disequilibrium (Table 3.6.2). The 
Fisher’s exact test was used to test for statistical significance.     
 
3.6.3.1. HIV status/Haplotype association 
The most common haplotype in both the HIV positive and the general populations 
was Hap2 (AAT). This haplotype occurred at a frequency of 0.41 and 0.37 in HIV 
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positive population and the general population, respectively (Table 3.6.3.1). The 
least common haplotype in both groups was Hap1 with frequencies of 0.1 and 
0.05 in HIV positive group and the general population, respectively. Overall, the 
haplotype frequencies were comparable between the groups, and the there was no 
significant difference in the distribution of frequencies between the two groups.  
 
Table 3.6.3.1. Haplotype distribution in HIV positive and the general populations 
Haplotype 
name 
Haplotype HIV positive 
(n=163) 
General population 
(n=52) 
Hap1 AAA 0.10      0.05  
Hap2 AAT 0.41      0.37 
Hap3 ACA 0.01      0.01 
Hap4 ACT 0.06      0.11 
Hap5 GAA 0.33     0.29 
Hap6 GAT 0.09      0.15 
Hap7 GCT 0.00   0.01 
 
 
3.6.3.2. Disease progression rate/haplotype association 
 Haplotype frequencies were compared between the groups that define the rate of 
HIV/AIDS disease progression (Table 3.6.3.2.1, Table 3.6.3.2.2 and Table 
3.6.3.2.3). The most common haplotype in all three rate-defining categories in 
both the compared groups were AAT and GAA. The frequency distribution 
among the study groups and there was no significant association between the 
haplotypes and the rate of the disease progression.    
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Table 3.6.3.2.1. Comparisons of haplotype frequencies between rapid progressors 
and long-term nonprogressors 
Haplotype 
name 
Haplotype Rapid progressors 
(n=19) 
Long-term 
nonprogressors (n=22) 
Hap1 AAA 0.09 0.02 
Hap2 AAT 0.38 0.36 
Hap3 ACT 0.03 0.05 
Hap4 GAA 0.39 0.45 
Hap5 GAT 0.09 0.12 
Hap6 GCT 0.02 0.00 
 
 
Table 3.6.3.2.2.  Haplotype frequencies and the rate of CD4+ cell count depletion. 
 
 
Table 3.6.3.2.3. Comparison of haplotypes in symptomatic and asymptomatic 
groups 
Haplotype 
name 
Haplotype Symptomatic, ≤5 yrs 
since diagnosis (n=19) 
Asymptomatic, >5 yrs 
since diagnosis (n=27) 
Hap1 AAA 0.09 0.06 
Hap2 AAT 0.38 0.33 
Hap3  ACT 0.03 0.09 
Hap4  GAA 0.39 0.44 
Hap5 GAT 0.10 0.08 
Hap6 GCT 0.02 0.0 
 
 
Haplotype 
name 
Haplotype  CD4+≤ 200, ≤5 yrs 
since diagnosis (n=18) 
CD4+>200, > 5 yrs since 
diagnosis (n=13) 
Hap1 AAA 0.09 0.04  
Hap2 AAT 0.46 0.38 
Hap3 ACA 0.02 0.0 
Hap4 ACT 0.04 0.04    
Hap5 GAA 0.36 0.50  
Hap6 GAT 0.03 0.04 
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3.6.3.3. TB status/Haplotype association 
In six haplotypes found in TB+ and TB- study groups, the most common ones 
were Hap2 and Hap4 (Table 3.6.3.3). The overall distribution of the haplotypes 
between the study groups was similar, no statistical significance was found. 
 
Table 3.6.3.3. Haplotype distribution in TB+ and TB- groups. 
Haplotype name Haplotype With TB (n=15) Without TB (n=79) 
Hap1 AAA 0.07 0.07  
Hap2 AAT 0.43 0.39 
Hap3 ACT 0.00 0.08 
Hap4 GAA 0.36 0.40 
Hap5 GAT 0.11 0.06 
Hap6 GCT 0.03 0.00 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 84 
CHAPTER 4 
DISCUSSION 
 
PCR amplification and direct sequencing of the 645 bp promoter fragment 
revealed six polymorphisms in 52 samples. This sample size was large enough to 
detect common polymorphisms that occur at a frequency of more than 2% in the 
population. The study population did not show any significant deviation from the 
expectations of Hardy-Weinberg equilibrium at any of the six polymorphic sites in 
the 52 sequenced samples. The indirect methods for detection of the four most 
common SNPs were successful. There was no significant deviation from the 
expectations of Hardy-Weinberg equilibrium at any of the four polymorphic sites. 
This showed that all the alleles of the polymorphic sites under investigation were 
accounted for.  
Sequencing of a 647 bp promoter region fragment in Ghanaians showed six 
polymorphisms as well. When put together, there are eight polymorphisms in a 
promoter fragment of about 650 bp in Africans, compared with three in African-
Americans. This high genetic diversity in these two African populations 
emphasizes that non-African populations have a subset of genetic variation found 
in Africans (Jorde et al, 1997; Tishkoff, 2002). 
 
The Hp1 and Hp2 alleles were found in equal frequencies in the study population. 
In Africans, Hp1 allele frequency ranges between 0.40 and 0.87 (Giblett, 1969). In 
South African populations, the frequency is between 0.44 and 0.58 (Nurse et al, 
1985). The frequency calculated for our study population was within this range.  
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An excess of the heterozygous genotype, Hp2-1 was observed at a frequency of 
0.57, nonetheless, the population did not deviate significantly from the 
expectations of the Hardy-Weinberg equilibrium.    
 
Using polyacrylamide gel electrophoresis, we were able to characterize the four 
major protein phenotypes in the population: Hp0, Hp1-1, Hp2-1 and Hp2-2. The 
Hp0 phenotype was characterized by the lack of protein bands on the gel. It was 
not investigated whether the Hp0 phenotype was because the protein was 
expressed at very low concentrations to be detected by gel electrophoresis 
(hypohaptoglobinemia), or due to a complete lack of protein expression 
(anhaptoglobinemia). And so, we did not discriminate between the two conditions 
and use Hp0 to describe both conditions.  
  
The genetic origin of the Hp0 phenotype has been reported to be deletion in 
Asians (Koda et al, 1998). But in Africans, where the frequency of the Hp0 
phenotype is high, the deletion was not found (Koda et al, 1998; Teye et al, 2003). 
The genetic basis for this phenotype in Ghanaians has been reported to be a single 
nucleotide base substitution in one of the functional sites of the promoter region, 
A to C at -61 (Teye et al, 2003).  Another haptoglobin mutation within the β-chain 
of Hp2 allele in Ghanaians was reported to be associated with Hp0 phenotype 
(Teye et al, 2004). In this study, there was only one individual homozygous for C 
at this site, and was found to be Hp0. Only 17% (7 out of 42) of Hp0 individuals 
had a C at site -61 in this study. Overall, there was no significant association 
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between the A to C substitution at -61 with phenotype Hp0. Rather, the Hp0 
phenotype was associated with -55G and -104A alleles. 
A high frequency of Hp0 individuals who were homozygous for G at -55 
polymorphic site was observed, even though the frequency of this genotype was 
low in the whole study population. The frequency of the G allele was 0.64, and the 
frequency of the homozygous genotype -55GG was 0.43. In 61% (11 out of 18) 
individuals who had Hp0, the -55GG genotype occurred with the -104AA 
genotype, and only 1 in 18 occurred with -104TT genotype. The -55 polymorphic 
site lies six base pairs downstream of the -61 site, which is one of the responsive 
sites to IL-6 (Oliviero and Cortese, 1989). The -55 polymorphic site is within the 
216 bp segment (between positions -186 and +30) of the haptoglobin promoter 
that responds to induction by IL-6 (Oliviero and Cortese, 1989). It has been 
reported (Maeda, 1991) that a G at position -55 can negatively affect haptoglobin 
protein expression. The combination of the promoter polymorphisms -55G and -
104A has been observed in Hp0 in black Americans (Maeda, 1991), although no 
conclusion on association between the promoter polymorphism and Hp0 
phenotype was drawn in that study because of small sample size.  The significant 
association between -55GG and -104AA genotypes suggests that there is a 
relationship between these genotypes and the Hp0 phenotype: carriers of one or 
both these genotypes are more likely to be Hp0.   
The Hp0 phenotype was also found to be more common in individuals who were 
genotypically Hp1-1 than in Hp2-2 individuals, and most common in Hp2-1 
individuals. The high frequency of the heterozygous genotype was not 
unexpected, since in the whole study population there was an excess of this 
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genotype. When comparing the distribution of the homozygous genotypes and the 
alleles in those with the Hp0 phenotype, Hp1-1 genotype and Hp1 allele 
frequencies were high, even though they were comparable in the whole study 
population. The frequency of Hp1 allele was 0.64, and Hp1-1 was 0.36. The 
distribution of haptoglobin genotypes in Hp0 individuals was significantly 
different.  Teye et al (2003) found an association of Hp2 allele with 
anhaptoglobinemia, and Hp1 allele with hypohaptoglobinemia. In this study, an 
association between the Hp1 allele and the Hp0 phenotype was observed. Other 
studies have found that Hp0 phenotype in Hp1 individuals is due to anomalous 
inheritance (Koda et al, 1998). As no distinction was made between 
anhaptoglobinemia and hypohaptoglobinemia in this study, it cannot be said 
which of these two conditions was associated with the polymorphisms. 
Nonetheless, these results show a fourth set of genetic polymorphism that is 
associated with the Hp0 allele. The association of Hp0 with different haptoglobin 
genetic polymorphisms suggests that this phenotype is caused by more than one 
polymorphism. These polymorphisms could be acting singly or in combination, 
with an exception of the Hpdel which is not found in Africans.  
  
The frequency of Hp0 phenotype in the entire study population was 0.30. These 
findings are in accordance with the previous studies in which the frequency of the 
Hp0 phenotype in Sub-Saharan Africa was reported to range between 10 and 40% 
(Constants, 1981). Since in the Gauteng region of South Africa there is no malaria 
endemic, the Hp0 phenotype found in this population would be due to genetic 
influences, and/or other factors.   
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In South African blacks, the frequency of Hp1 allele ranged between 0.43 and 
0.59, which is within the reported range in Africans (Giblett, 1989; Nurse et al, 
1985). The Zulu group sample size was large enough to get a close estimation of 
the frequency of the allele in the group; the other groups were present in small 
numbers in the study population. The allele frequencies were close in Zulu, Xhosa 
and Tswana groups, Xhosa group frequency being the median point. Pedi and 
Tsonga groups showed very close frequencies. The Sotho group (Southern Sotho) 
showed the lowest frequency, lower than the previously reported one (Nurse et al, 
1985). The expectations were that the frequencies in the groups under the Nguni 
group (Zulu and Xhosa groups), and the groups under the Sotho-speakers (Pedi, 
Tswana and Sotho groups) would show frequencies be very similar to each other 
(Lane et al, 2001). Intercultural mating, which was common in our study 
population, and the small numbers of other ethnic groups would explain the shift 
from the expected groupings. Nevertheless, the frequency distribution in this study 
does not differ significantly from a previous study where Zulu, Xhosa, Swazi, 
Tswana and Sotho groups showed very similar frequencies (Nurse et al, 1985).  
Although there are differences in frequencies among South African blacks, 
different languages, cultures and geographic locations, they all originate from the 
Bantu expansion and share a common ancestral population (Lane et al, 2001) 
which explains the small difference in allele frequencies.    
 
The very strong linkage disequilibrium between the promoter region site -61 and 
the coding region was not unexpected. Site -61 is one of the IL-6 response 
elements. The strong association is due to the fact that this site correlates with the 
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coding region. Sites -55/-61, -61/-104 and -55/-104 showed strong to very strong 
linkage disequilibrium. These site are close to each other and they demonstrate the 
D
-55,-61 > D-61,-104 > D-55,-104 order, which indicates that the closer the loci, the 
greater the linkage disequilibrium (Lewontin, 1964).   It is not clear why -61/-295 
showed such strong linkage disequilibrium. The association is stronger than that 
of -55/-104 and -61/-104 but the sites are farther apart, and site -295 is not a 
functional site. 
 
Among the four polymorphisms of the promoter region, -61A/C showed marginal 
association with susceptibility to HIV infection (P=0.045). The frequency of the C 
allele was higher in the general population than in the HIV positive population. As 
mentioned previously, position -61 is one of the response elements for the inducer 
of the protein expression. The A to C base substitution at this site reduces the 
activity of the promoter (Maeda, 1991). Haptoglobin protein is indirectly involved 
in the entry of the HIV into the host cell during infection (El Ghamati, 1996) or 
cell to cell transmission (Quaye et al, 2000). The effect of the reduced protein 
expression on the infection by HIV has been reported (Quaye et al, 2000) where 
the Hp0 phenotype was more common in HIV negative individuals. A previous 
study reported the association of Hp0 and the -61C allele (Teye et al, 2003). 
Although in this study there was no significant association between the -61C allele 
and Hp0, the decreased protein expression in -61C individuals would explain the 
association between the reduced risk of HIV infection and the -61C allele. We 
also observed a high frequency of Hp0 phenotype in the general population, 0.43 
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compared with 0.25 in the HIV positive population, though the difference was not 
statistically significant.  
 
The results of this study showed no association between the haptoglobin 
genotypes and susceptibility to HIV infection. The Hp1 and Hp2 allele frequencies 
did not differ significantly between the HIV positive and the general populations. 
This implied that the Hp1 and Hp2 alleles have the same chances of HIV infection. 
These findings are in agreement with the study done in Ghana (Quaye et al, 2000). 
 
There was no association between susceptibility to infection TB and any of the 
polymorphisms. Previous studies reported that polymorphism in the coding region 
of the haptoglobin gene is associated with susceptibility TB infection (Fedoseeva 
et al, 1993) and outcome after treatment initiation (Kasvove et al, 2000). In this 
study, the effect of the genetic polymorphism on severity of the disease and 
treatment outcome remained uninvestigated. It could happen that the 
polymorphisms affect the outcome after treatment initiation or severity of the 
disease in our population. Thus, the lack of significant association between 
haptoglobin polymorphism and TB infection in this study does not mean the 
complete lack of association between TB and haptoglobin polymorphism.  
 
Even though the total sample size was large, only a few samples had usable 
clinical data for studying the impact of the haptoglobin polymorphism on the rate 
of the disease progression. In addition, the clinical data we had was self reported, 
which made it unreliable to a certain extent. That made it difficult to conclude 
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with certainty that there was a complete lack of significant correlation between 
other polymorphisms and the rate of progression.  
There was no statistically significant association between any of the 
polymorphisms, including the coding region polymorphism which has been 
previously reported to be associated with the rate of the disease progression in 
Europeans (Delanghe et al, 1996) and Ghanaians (Quaye et al, 2000).  
 
Because CD4+ cell depletion is one of the indicators of the rate of HIV/AIDS 
progression (Carré et al, 1998), the association between polymorphism and the 
rate of CD4+ cell depletion was examined. Although there was no significant 
association between the polymorphisms and the rate of CD4+ cell depletion, two 
polymorphisms are noteworthy: -104A/T and the coding region. A high frequency 
of -104AT genotype (0.72) was observed in the group with faster rate of CD4+ 
cell depletion, and the higher frequency of -104AA genotype (0.38) in the group 
with slower rate of cell depletion. It must be pointed out that the frequency of AT 
in the whole study population was 0.46, meaning there was no excess of this 
genotype, and the AA genotype was found in lower frequency in the whole 
population (0.19). The -104 site is within the IL-6 response segment, between 
positions -186 and +30 (Oliviero and Cortese, 1989). It is possible that variation at 
this site could have an effect on the level of protein expression and the disease, 
though no conclusion could be drawn at this stage. The effect of this 
polymorphism on the activity of the promoter needs to be studied, and its possible 
effects on the rate of CD4+ cell destruction. 
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In the coding region polymorphism, an excess of the Hp2-1 genotype was 
observed in the whole study population and all the other categories, but not in the 
group with faster rate of CD4+ cell depletion (and the general population). High 
frequencies of Hp2-2 genotype and Hp2-2 protein phenotype were observed in the 
group with the faster rate of CD4+ cell depletion. The association between CD4+ 
cell depletion and Hp2-2 protein phenotype has been reported (Quaye et al, 2000). 
Since CD4+ cell destruction is one of the indicators of the rate of HIV/AIDS 
progression (Carré et al, 1998), the high frequency of Hp2-2 in the group with 
faster rate of CD4+ cell depletion is in agreement with the previous study of 
Delanghe et al (1996), where the association of this protein phenotype and the 
faster rate of HIV/AIDS progression was reported, but the difference was not 
statistically significant.  
 
Another frequency difference which was not statistically significant was in the 
Hp0 phenotype. The frequency of this phenotype was higher in the group with a 
slower rate of CD4+ cell depletion. This suggested a possibility of association 
between the Hp0 phenotype with the slower rate of the disease progression, as has 
been reported previously (Quaye et al, 2000). 
  
We looked at the haplotypes for three polymorphic sites (-55, -61 and -104) and 
their effect on TB and HIV infection, and the rate of HIV/AIDS disease 
progression. The reason for taking haplotypes for three polymorphic sites is that 
our sample size was small; taking haplotypes for all five sites would result in a 
large number of haplotypes with few samples of each. The polymorphic sites 
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chosen are close to each other and they show strong to very strong linkage 
disequilibrium and they are found within the IL-6 response segment. There was no 
association between any of the haplotypes and either susceptibility or the rate of 
disease progression. The lack of correlation between the haplotype for these 
polymorphic sites and the disease status was not unexpected as there was no 
significant association between -55 and -104 polymorphic sites and the disease 
status, and the association with -61 was marginal.  
 
The hemoglobin clearance efficiency differs between haptoglobin types. The poor 
prognosis in Hp2-2 individuals with HIV was explained by retention of iron in the 
plasma by Hp2-2 phenotype that leads to oxidative stress, resulting in high rate of 
viral replication (Delanghe et al, 1996). In this study no association was found 
between the haptoglobin genotypes/phenotypes that have been previously reported 
to be associated with TB and the rate of HIV/AIDS progression. There are two 
possible explanations for this. One, that is more likely, could be that our sample 
size was small. Alternatively, it could be explained by the findings of Kasvosve et 
al (2002) that iron metabolism is not influenced by haptoglobin phenotypic 
variation in African blacks. This could also explain the lack of association 
between Hp phenotypes and TB infection in the Zimbabweans (Kasvove et al, 
2000). There are contradicting results regarding susceptibility to malaria and Hp 
phenotypes (Trape and Fribourg-Blanc, 1988; Joshi et al, 1987; Elagib et al, 1998; 
Aucan et al, 2002) which could point out population diversity or differences in the 
functioning of haptoglobin. 
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South Africa has the highest number of people living with HIV/AIDS than any 
country, and the prevalence is still increasing. That poses a challenge to 
researchers to find a cure for the millions of people already infected with the 
virus, and a vaccine for those who are uninfected. Studying the influence of 
genetics on susceptibility to HIV infection and the rate of the disease progression 
is another way that could lead to treatment and prevention of AIDS. A number of 
genes have been reported to be associated with HIV infection and disease 
progression; most of these studies have been done in non-Africans. These 
associations may not be a general picture for all the populations.  As genetic 
diversity is high in Africans, searching for additional polymorphisms found in 
Africans, and determining whether these polymorphisms have an impact on 
susceptibility to HIV infection and the rate of the disease progression may lead to 
the solving of the HIV/AIDS endemic. 
  
The findings of this study present a need to further investigate the impact of 
haptoglobin genetic variation on susceptibility to HIV infection and the rate of 
HIV/AIDS disease progression in black South Africans. The study should be done 
on a long term established cohort with large sample size.  
The novel association of Hp0 phenotype and -55GG and -104AA genotypes in 
South Africans also needs further investigation. It should be investigated whether 
the -55GG and -104AA genotypes are associated with anhaptoglobinemia or 
hypohaptoglobinemia, and if so how these genotypes affect the level of 
haptoglobin expression.       
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CONCLUSIONS  
Until now, the effect of polymorphism in the promoter region of the haptoglobin 
gene on HIV infection and the rate of progression of AIDS has not been reported. 
We have found a significant association between the -61C allele and low risk of 
HIV infection. This association could be related to the low levels of haptoglobin 
protein expression caused by the A-C base substitution at position -61. Since we 
have looked at small sample sizes, further investigation on larger population size 
with reliable clinical data need to be done to confirm this.  
 The significant association of the Hp0 phenotype with -55GG and -104AA 
genotypes suggests that there is a relationship between these genotypes, singly or 
in combination, and Hp0 phenotype, not that they are exactly the cause of the Hp0 
phenotype because the genotypes were also found in the other phenotypes. The 
association of Hp1-1 genotype with Hp0 could be due to anomalous inheritance, 
or related to the level of protein expression in Hp1-1 individuals. 
We have also observed frequency differences which were not statistically 
significant, but noteworthy: a high frequency of -104AA genotype and Hp0 
phenotype in individuals with a slower rate of CD4+ cell depletion; high frequency 
of -104AT genotype and Hp2-2 phenotype in individuals with a faster rate of 
CD4+ cell depletion. The observed associations, both the statistically significant 
and the one that were not statistically significant, portray a need to do further 
investigations on the effect of the polymorphisms in the noncoding region of the 
haptoglobin gene on HIV infection and the rate of disease progression. Since few 
samples had usable data in this study, further investigation needs to be done on a 
large established cohort with more reliable clinical data, including the rate of viral 
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load increase, would likely lead to a concrete conclusion. If significant 
associations are found, they could be used in drug development and treatment 
trials.   
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APPENDIX 1 
  
 Table E.1. Raw data – Sample genotypes and phenotypes  
        
Sample Group -55 -61 -104 -295 Hp Genotype Phenotype 
206 W AG A A T Hp2-1 Hp0 
207 W A A AT CT Hp1-1 Hp0 
208 W AG A AT CT Hp2-1 Hp0 
209 W AG A AT CT Hp1-1 Hp0 
210 W A A T CT Hp2-2 Hp2-2 
211 W A AC T CT Hp2-1 Hp2-1 
212 W A A T CT Hp2-1 Hp2-1 
213 W AG A AT T Hp2-1 Hp2-1 
214 W G A A T Hp1-1 Hp0 
215 W A A T CT Hp2-1 Hp2-1 
216 W AG A T CT Hp2-1 Hp2-1 
217 W A A T T Hp2-2 Hp2-2 
218 W AG AC T CT Hp2-1 Hp0 
219 W G A A CT Hp1-1 Hp0 
220 W AG A T CT Hp2-1 Hp2-1 
221 W AG A AT T Hp2-1 Hp2-1 
222 W AG A T T Hp2-2 Hp2-2 
223 W G A AT CT Hp1-1 Hp0 
224 W A A T CT Hp2-2 Hp2-2 
225 W G A AT CT Hp1-1 Hp0 
226 W A A T CT Hp2-1 Hp2-1 
227 W AG AC AT T Hp2-1 Hp2-1 
228 W G A T T Hp1-1 Hp0 
229 W AG A A T Hp2-1 Hp2-1 
230 W AG A AT T Hp2-1 Hp2-1 
231 W AG A AT T Hp1-1 Hp1-1 
232 W AG A AT T Hp2-1 Hp0 
233 W G A AT T Hp2-1 Hp2-1 
234 W AG AC A T Hp2-1 Hp0 
235 W AG A A T Hp1-1 Hp0 
236 W A A T CT Hp1-1 Hp0 
237 W AG AC AT T Hp2-1 Hp0 
238 W AG A AT T Hp1-1 Hp0 
239 W AG AC AT CT Hp2-2 Hp2-2 
240 W AG A AT CT Hp2-2 Hp2-2 
241 W AG A T T Hp2-1 Hp2-1 
242 W AG AC AT CT Hp2-2 Hp0 
243 W AG A AT T Hp1-1 Hp1-1 
244 W G A AT T Hp2-2 Hp0 
245 W AG A AT CT Hp2-1 Hp2-1 
A001 W G AC T T Hp2-2  
A002 W G A T T Hp2-1  
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Sample genotypes and phenotypes (continued) 
 
Sample Group -55 -61 -104 -295 Hp Genotype Phenotype 
A003 W AG A AT T Hp2-1 Hp2-1 
A004 W A AC T T Hp2-2 Hp2-2 
A005 W AG AC AT T Hp2-1 Hp2-1 
A006 W A AC T T Hp2-2 Hp2-2 
A007 W A AC T T Hp2-2 Hp2-2 
A008 W AG A T T Hp2-2 Hp2-2 
A009 W AG AC AT T Hp2-1 Hp2-1 
A010 W A AC T T Hp2-2 Hp2-2 
101 P G A T T Hp2-2 Hp2-2 
102 P G A AT TC Hp2-1 Hp2-1 
103 P G A A T Hp1-1 Hp0 
104 P G A AT T Hp2-1 Hp0 
105 P G A AT TC Hp1-1 Hp0 
106 P G A A T Hp1-1 Hp0 
107 P A A T T Hp2-1 Hp2-1 
108 P G A AT T Hp2-1 Hp2-1 
109 P A A T T Hp2-1 Hp2-1 
110 P G A A T Hp1-1 Hp0 
111 P G A AT T Hp2-1 Hp0 
112 P AG A AT T Hp2-1 Hp2-1 
113 P A A T T Hp2-1 Hp0 
114 P AG A AT T Hp2-1 Hp0 
115 P AG A AT T Hp2-1 Hp2-1 
116 P A AC T TC Hp2-1 Hp2-1 
117 P AG AC T T Hp1-1 Hp0 
118 P AG A AT TC Hp1-1 Hp1-1 
119 P A A T T Hp2-1 Hp2-1 
120 P A A T T Hp2-2 Hp2-2 
121 P AG A A TC Hp1-1 Hp1-1 
122 P AG A AT TC Hp2-1 Hp2-1 
123 P A A T T Hp2-2 Hp2-2 
124 P G A A TC Hp2-1 Hp0 
125 P AG A AT TC Hp2-1 Hp2-1 
126 P AG A AT T Hp2-1 Hp2-1 
127 P AG AC AT TC Hp2-1 Hp0 
128 P A AC T T Hp2-1 Hp2-1 
129 P AG A AT T Hp2-1 Hp2-1 
130 P AG A AT T Hp2-1 Hp2-1 
131 P AG A AT T Hp2-1 Hp2-1 
132 P A AC T T Hp2-1 Hp2-1 
133 P AG A AT TC Hp2-1 Hp0 
135 P G A A T Hp2-1 Hp0 
136 P A A T T Hp2-1 Hp0 
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Sample genotypes and phenotypes (continued) 
 
Sample Group -55 -61 -104 -295 Hp Genotype Phenotype 
137 P AG A AT T Hp2-1 Hp2-1 
138 P AG A AT T Hp2-1 Hp2-1 
139 P A AC T T Hp2-2 Hp2-2 
140 P A AC T T Hp2-2 Hp2-2 
141 P A A T T Hp2-1 Hp2-1 
142 P A C T T Hp2-2 Hp0 
143 P AG A AT TC Hp2-1 Hp2-1 
144 P AG A AT TC Hp2-1 Hp2-1 
145 P G A A T Hp1-1 Hp1-1 
146 P G A A C Hp2-1 Hp0 
147 P A A AT T Hp1-1 Hp1-1 
148 P AG A AT T Hp2-2 Hp2-2 
149 P G A A TC Hp2-1 Hp2-1 
150 P AG A AT TC Hp2-1 Hp2-1 
151 P AG A AT T Hp2-1 Hp0 
152 P G A AT TC Hp2-1 Hp2-1 
153 P A AC AT T Hp2-2 Hp2-2 
154 P G A A TC Hp2-1 Hp0 
155 P AG A AT TC Hp2-1 Hp2-1 
156 P A A AT T Hp2-1 Hp2-1 
157 P G A AT T Hp2-1 Hp2-1 
158 P AG A AT T Hp2-1 Hp2-1 
159 P AG A AT T Hp2-2 Hp2-2 
160 P G A A TC Hp2-1 Hp2-1 
161 P AG AC AT T Hp2-1 Hp2-1 
162 P AG A T T Hp2-1 Hp2-1 
163 P G A A TC Hp2-1 Hp0 
164 P AG A AT TC Hp2-1 Hp2-1 
166 P AG A AT T Hp2-1 Hp2-1 
167 P A A AT T Hp2-2 Hp2-2 
168 P A A AT T Hp2-1 Hp0 
169 P A AC T T Hp2-2 Hp2-2 
170 P AG A A T Hp2-1 Hp2-1 
171 P AG A AT TC Hp2-1 Hp2-1 
172 P AG A AT T Hp2-1 Hp0 
173 P AG A T TC Hp2-1 Hp2-1 
175 P AG A T T Hp2-1 Hp2-1 
176 P AG A AT T Hp2-1 Hp0 
177 P AG A T T Hp2-1 Hp2-1 
178 P AG A A C Hp1-1 Hp1-1 
179 P AG A AT TC Hp2-2 Hp2-2 
180 P A A AT T Hp2-2 Hp2-2 
181 P G A A T Hp2-1 Hp2-1 
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Sample genotypes and phenotypes (continued) 
 
Sample Group -55 -61 -104 -295 Hp Genotype Phenotype 
182 P A A T T Hp2-1 Hp2-1 
183 P AG A T TC Hp1-1 Hp1-1 
184 P G A A TC Hp2-1 Hp2-1 
185 P G A A C Hp1-1 Hp1-1 
186 P A AC T C Hp2-2 Hp2-2 
187 P A A T T Hp2-1 Hp2-1 
188 P G A A T Hp2-1 Hp0 
189 P AG A AT T Hp1-1 Hp1-1 
190 P A A T TC Hp2-1 Hp2-1 
191 P G A AT C Hp1-1 Hp1-1 
192 P A A T TC Hp2-1 Hp2-1 
193 P A A T T Hp2-1 Hp2-1 
194 P AG A AT TC Hp2-1 Hp2-1 
195 P AG A AT C Hp2-1 Hp2-1 
196 P AG A A TC Hp2-1 Hp2-1 
197 P AG A AT T Hp2-1 Hp2-1 
198 P AG A AT TC Hp2-1 Hp2-1 
199 P AG A AT TC Hp2-1 Hp2-1 
200 P AG A AT T Hp2-1 Hp2-1 
201 P G A AT TC Hp2-2 Hp2-2 
203 P A A T TC Hp2-2 Hp2-2 
204 P AG AC AT T Hp2-1 Hp2-1 
205 P A AC AT T Hp2-1 Hp2-1 
220+ P AG A A T Hp2-1 Hp0 
525 171 CG AG A AT TC Hp2-1  
525 327 CG A A T T Hp2-2  
525 301 CG AG A T T Hp2-1  
525 343 CG AG A AT T Hp1-1  
525 316 CG AG A A T Hp2-1  
525 298 CG A A T T Hp2-2  
525 160 CG A A A T Hp1-1  
525 028 CG G A A T Hp1-1  
536 031 CG AG AC AT T Hp2-1  
536 121 CG A A T T Hp2-1  
536 107 CG AG AC A T Hp2-1  
536 015 CG A A T T Hp2-1  
536 149 CG G A A C Hp2-1  
536 173 CG AG AC AT T Hp2-1  
541 144 CG A A AT C Hp2-1  
541 085 CG A A T T Hp2-2  
541 049 CG A A T T Hp2-1  
541 062 CG AG A A T Hp1-1  
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Sample genotypes and phenotypes (continued) 
 
Sample Group -55 -61 -104 -295 Hp Genotype 
541 036 CG AG AC T T Hp2-2 
541 073 CG A A T T Hp2-1 
541 115 CG A A T TC Hp2-1 
541 131 CG AG A A TC Hp2-1 
541 178 CG A AC T T Hp2-2 
541 098 CG A A T T Hp2-2 
541 180 CG AG A AT TC Hp1-1 
541 193 CG AG A A TC Hp1-1 
541 228 CG A AC T T Hp2-2 
541 234 CG AG A A T Hp1-1 
541 242 CG AG A T T Hp2-1 
541 256 CG G A T T Hp1-1 
541 353 CG A AC T T Hp1-1 
615 015 CG A A T T Hp2-1 
615 093 CG AG AC A T Hp2-1 
615 080 CG AG A AT T Hp1-1 
615 078 CG AG A A T Hp1-1 
615 067 CG AG A A T Hp1-1 
615 059 CG A A AT T Hp2-2 
615 044 CG AG A AT TC Hp1-1 
615 031 CG AG A AT T Hp2-1 
615 026 CG AG A AT TC Hp1-1 
615 107  CG A A T TC Hp2-2 
615 110 CG A A AT T Hp2-2 
615 121 CG AG A AT T Hp2-1 
615 136 CG AG A AT T Hp2-1 
615 325 CG A A AT T Hp2-2 
615 332 CG AG A AT TC Hp2-1 
615 340 CG AG A T T Hp2-1 
615 377 CG A A T T Hp2-2 
615 381 CG AG A T TC Hp1-1 
615 394  CG AG A AT TC Hp2-1 
615 406 CG AG A AT TC Hp1-1 
615 366 CG AG A A TC Hp1-1 
616 017 CG AG A AT T Hp2-2 
616 042 CG AG A T TC Hp1-1 
616 091 CG AG A A T Hp2-1 
616 358 CG A A AT T Hp2-2 
616 445 CG G A AT T Hp2-1 
616 453 CG A A T T Hp1-1 
616 457 CG A A A T Hp1-1 
616 472 CG A AC AT TC Hp2-2 
616 486 CG AG A AT TC Hp2-1 
616 499 CG AG A A T Hp2-1 
616 503 CG AG A T T Hp1-1 
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   P = Samples collected from HIV positive subjects 
  W = With unknown HIV status 
CG = Samples provided by Dr Clive Gray (also from HIV positive subjects) 
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